DNA damage responses in human skin and blood lymphocytes in relation to late normal tissue effects following radiotherapy for early breast cancer by Chua, MLK
DNA DAMAGE RESPONSES IN  
HUMAN SKIN AND BLOOD 
LYMPHOCYTES IN RELATION TO  
LATE NORMAL TISSUE EFFECTS 
FOLLOWING RADIOTHERAPY FOR 
EARLY BREAST CANCER
MELVIN LEE KIANG CHUA, M.B.B.S., F.R.C.R.
A thesis submitted as part of the requirements for the Degree of Doctor of 
Philosophy at the University College London Faculty of Medical Sciences.
2009–2013
I, Melvin Lee Kiang Chua, confirm that the work presented in this 
thesis is my own. Where information has been derived from other 
sources, I confirm that this has been indicated in the thesis.
23th May 2013
For Dad and Mum,
My Dearest Viola
and Elliott

Table of  Contents
Acknowledgements ix
Abstract xi
I. Introduction 1
I.1 Normal tissue responses following radiotherapy 1
I.1.1 General principles of radiation-induced effects 1
I.1.2 Cellular responses following irradiation of early 
 responding tissues 1
I.1.3 Cellular responses relating to late radiation effects 3
I.1.4 Determinants of acute and late normal tissue responses 4
I.1.4.1 Treatment-related factors 4
I.1.4.2 Organ-related factors 5
I.1.4.2 Patient-related factors: Evidence for an intrinsic 
 component in inter-individual variability of normal 
 tissue responses 6
I.2 Predicting normal tissue radiosensitivity 7
I.2.1 Clinical value of predicting intrinsic normal tissue 
 radiosensitivity 7
I.2.2 Biological considerations for predictive assays of 
 radiosensitivity 8
I.2.2.1 In vitro cellular radiosensitivity as a biomarker of 
 clinical response to radiotherapy 8
I.2.2.2 Inter-cell/tissue variation in cellular and clinical 
 radiosensitivity 10
I.2.2.3 Association between normal tissue and tumour 
 radiosensitivity 11
I.2.3 Assays for predicting normal tissue radiosensitivity 11
I.2.4 Chromosomal radiosensitivity assay 12 
I.2.4.1 Correlation between chromosomal damage and cell
 survival 12
I.2.4.2 In vitro chromosomal radiosensitivity as a predictive
 marker of normal tissue responses after radiotherapy 12
I.2.5 Assays of DNA damage responses 13
I.2.5.1 Overview of cellular responses related to ionising
 radiation-induced DNA damage 13
I.2.5.2 NHEJ and HR in the repair of ionising radiation-
 induced DSB 16
vi Contents
I.2.5.3 Biological principles underlying the association 
 between in vitro DNA damage responses and 
 normal tissue radiosensitivity 18
I.3 References 21
II. Project overview 30
II.1 Background 30
II.1.1 Clinical considerations in the selection of ‘over-
 responders’ and ‘controls’ 30
II.1.2 Are cell-based assays valid systems for predicting normal 
 tissue radiosensitivity? 31
II.2 Aims and outline 31
II.3 References 33
III. Original research 35
III.1 Inter-individual and inter-cell type variation in residual DNA 
 damage after in vivo irradiation of human skin 35
III.1.1 Abstract 35
III.1.2 Introduction 35
III.1.3 Materials and methods 36
III.1.3.1 In vivo irradiation of skin of breast cancer patients 36
III.1.3.2 53BP1 immunohistochemistry in skin sections 36
III.1.3.3 Statistical methods 37
III.1.4 Results 38
III.1.4.1 Patients 38
III.1.4.2 Quantification of 53BP1 foci in different skin 
 cell types 38
III.1.4.3 Correlation of 53BP1 foci in duplicate skin biopsies 39
III.1.4.4 Inter-individual variation in residual foci levels 39
III.1.4.5 Inter-cell type variation in residual foci levels 42
III.1.5 Discussion 42
III.1.6 Conclusions 44
III.1.7 References 44
III.2 DSB repair following in vivo and ex vivo irradiation of skin tissues 
 and blood lymphocytes in relation to late effects of breast 
 radiotherapy 46
III.2.1 Abstract 46
III.2.2 Introduction 46
III.2.3 Materials and methods 47
III.2.3.1 Selection of cases and controls 47
III.2.3.2 Skin irradiation, 53BP1 immunohistochemistry, 
 and foci analyses of skin sections 48
Contents vii
III.2.3.3 Peripheral blood separation and G0 blood 
 lymphocyte irradiation 50
III.2.3.4 DSB in ex vivo irradiated G0 blood lymphocytes 50
III.2.3.5 Statistical methods 51
III.2.4 Results 51
III.2.4.1 Cases and controls 51
III.2.4.2 Residual foci levels of in vivo irradiated skin in 
 cases and controls 52
III.2.4.3 Foci levels of ex vivo irradiated G0 blood 
 lymphocytes in cases and controls 55
III.2.5 Discussion 56
III.2.6 Conclusions 59
III.2.7 References 59
III.3 Residual DNA and chromosomal damage in ex vivo irradiated 
 blood lymphocytes correlated with late normal tissue responses to
 breast radiotherapy 60
III.3.1 Abstract 60
III.3.2 Introduction 61
III.3.3 Materials and methods 61
III.3.3.1 Selection of severe cases and controls 61
III.3.3.2 Isolation, ex vivo irradiation, and γH2AX/53BP1 
 co-immunostaining of G0 blood lymphocytes 62
III.3.3.3 Chromosomal radiosensitivity in blood 
 lymphocyte metaphases after ex vivo irradiation 62
III.3.3.4 Statistical methods 62
III.3.4 Results  63
III.3.4.1 Patients 63
III.3.4.2 γH2AX/53BP1 foci levels in cases and controls 63
III.3.4.3 Chromosomal aberration levels in cases and 
 controls 64
III.3.4.4 Association between residual foci in G0 blood 
 lymphocytes and chromosomal aberrations in 
 lymphocyte metaphases 65
III.3.5 Discussion 66
III.3.6 Conclusions 70
III.3.7 References 70
III.4 DSB repair and induction of apoptosis following ex vivo 
 irradiation of blood lymphocytes in relation to late normal tissue 
 responses of breast radiotherapy patients 72
III.4.1 Abstract 72
III.4.2 Introduction 73
III.4.3 Materials and methods 74
III.4.3.1 Severe cases, controls, and healthy volunteers 74
viii Contents
III.4.3.2 Ex vivo irradiation and immunostaining of G0 
 blood lymphocytes 74
III.4.3.3 Radiation-induced apoptosis in irradiated G0 
 blood lymphocytes 74
III.4.3.4 Treatment with small molecule inhibitors 75
III.4.3.5 Statistical methods 75
III.4.4 Results 75
III.4.4.1 Increased γH2AX/53BP1 foci levels 24 hours after 
 4 Gy in cases compared to controls 75
III.4.4.2 Comparable apoptosis levels 48 hours after 8 Gy 
 between cases and controls 75
III.4.4.3 Induction of apoptosis is dependent on DSB 
 end-joining and ATM kinase activation in G0 
 blood lymphocytes 76
III.4.4.4 Impaired DSB repair cellular phenotype in a case 
 with severe clinical radiosensitivity 78
III.4.5 Discussion 82
III.4.6 Conclusions 85
III.4.7 References 85
IV. General discussion 87
IV.1 Project summary 87
IV.2 Challenges and clinical impact of predictive testing of normal 
 tissue damage 89
IV.2.1 Controversies of case-control studies testing for predictive 
 markers of normal tissue radiosensitivity 89
IV.2.2 DSB repair as a biomarker of clinical radiosensitivity 92
IV.2.3 Potential clinical impact of predictive testing of normal 
 tissue radiosensitivity 93
IV.2.3.1 Screening for ‘over-responders’ to radiotherapy 93
IV.2.3.2 Modifying radiotherapy dose prescriptions 
 according to individual intrinsic radiosensitivity 95
IV.2.3.3 Improving therapeutic ratio: relationship 
 between tumour control and late normal tissue 
 complication probability models 97
IV.2.3.4 Potential strategies for the use of normal tissue 
 radiosensitivity assays 98
IV.3 Future perspectives 99
IV.4 Final conclusions 100
IV.5 References 100
Glossary 105
Appendix: Peer-reviewed publications and abstracts 107
Acknowledgments
There are a number of people I like to thank for their significant and unwavering 
support over the years. To my supervisors, John Yarnold, Kai Rothkamm, and Susan 
Short, thank you for the invaluable mentoring. It seemed not too long ago when we first 
gathered on a cold wintry morning back in 2009 discussing about the different 
possibilities for my PhD project. It is incredible recalling the summers and winters that 
have since passed, and now, I am at the end of this fulfilling journey. Through our 
intellectual interactions, I have learnt a lot, and for this, I am eternally grateful. To my 
colleagues at the Health Protection Agency, in particular, Jayne Moquet, Liz Ainsbury, 
Stephen Barnard, and Donna Lowe, thank you for the wonderful friendships. Lunches 
became a lot less boring with you all around. To Simon Bouffler, thank you for the 
generosity extended in hosting me as an external student at the HPA. To Simon Horn, 
gradually through the years, we have grown to know each other very well. I will treasure 
memories of the late nights wandering the eerily quiet corridors of the HPA, the 
occasional nights out in Oxford, not forgetting the vicious moments of intellectual 
sword play. Thank you for being a dependable colleague and friend. To Sue Davies and 
Lone Gothard, my collaborators from the Institute of Cancer Research, it is impossible 
to compliment enough your contributions to my work. Your enthusiasm, support, and 
assistance are second to none, and quite clearly, you were both integral to the smooth 
progression of this project. To John Hartley, thank you for agreeing without reservation 
to be my secondary supervisor. To Julie Olszewski, I cannot ask for a graduate tutor, 
kinder, more considerate and compassionate than yourself. You were always there to 
listen when needed, and no matter how dire the situation, you never fail to provide a 
solution. I am truly indebted for the support you have provided me throughout. To my 
family, Dad, Mum, Kevin, Joan, Brian, Dad-, Mum-in-law, and Rickie, thank you for 
supporting me unreservedly through this adventure. Particularly to my Dad and Mum, 
thank you for taking care of your little boy and never once doubting his choices in 
life, however unconventional they are. To Kevin and Brian, thank you for being such 
wonderful brothers. Although miles apart, the constant phone and video conversations 
kept us close, and you never cease to encourage. To Daniel, my dear friend for the past 
20 years, thank you for sharing my convictions and beliefs. Last but not least, to Viola, 
my dearest wife, the past 4 years have been such a journey, filled with happiness, 
laughter, tears, and anguish. You are my greatest critic and fan, my trusting confidant, 
and my lifelong soul mate. Thank you for bringing Elliott into our lives, and the 7th 
October 2011 will forever remain the happiest day in my life. Your contributions to the 
fruition of this piece of work is as much as mine, and this thesis is hereby dedicated to 
you and our son.

Abstract
In this study, we test the hypothesis that an in vivo DNA double-strand break (DSB) 
repair assay performed in irradiated human skin correlates with severity of late 
toxicities following breast radiotherapy, as opposed to the same assay performed in ex 
vivo irradiated blood lymphocytes. Applying a comparative analysis approach, levels 
of residual DSB were judged to be significantly higher among patients who presented 
with late adverse effects in their breasts (cases) than controls who had minimal/no 
effects, but this was only observed in blood lymphocytes. In conjunction with this 
observation, although DSB repair was comparable between different skin cells, residual 
DSB levels were not correlated between skin cells and blood lymphocytes of the same 
patients. These findings suggest that cellular DSB repair may be influenced by factors 
relating to the tissue microenvironment, and support the notion that blood lymphocytes 
represent a valid cellular system for testing of predictive markers of normal tissue 
radiosensitivity. Next, chromosomal radiosensitivity and radiation-induced apoptosis 
were tested as markers of clinical radiosensitivity among a subset of severe cases and 
matched controls. Unlike levels of apoptosis in irradiated blood lymphocytes which 
were comparable between both groups of patients, levels of chromosomal aberrations 
were significantly higher in irradiated blood lymphocyte metaphases of severe cases, 
suggesting that likewise to DSB repair, chromosomal radiosensitivity could be a 
potential marker of clinical radiosensitivity. Crude tests of association were performed 
to determine if different cellular radiation responses were correlated within the same 
individuals. Levels of residual DSB were closely related to the formation of excess 
acentric fragments in the same patients, while separately, induction of apoptosis was 
found to be independent of DSB repair. Interactions between DSB repair and apoptosis 
induction were further examined and a mechanistic model linking these radiation 
responses is proposed.

IIntroduction
I.1  NORMAL TISSUE RESPONSES FOLLOWING RADIOTHERAPY
I.1.1 General principles of  radiation-induced effects
Therapeutic efficacy of radiotherapy in the treatment of cancers is determined by its 
ability to control the primary tumour weighed against the detrimental effects to 
normal tissues. Based on the principles of radiotherapy planning, it is inevitable that 
normal tissues surrounding the tumour are irradiated despite the availability of 
modern radiotherapy techniques capable of greater precision in target irradiation. 
Depending on the type of tissue, tolerance doses to irradiation vary, and symptoms of 
radiation-induced injury could range from mild acute effects such as erythema and 
mucositis in the epithelium to severe late complications including myelitis and necrosis 
of the spinal cord [1]. Radiation injuries are commonly classified as either acute or late 
effects. Unlike acute effects which are typically experienced during the course of 
radiotherapy, late effects occur months to years after completion of treatment, and 
are irreversible, progressive, and dose-limiting consequences. Rarely, significant 
aggravation of acute effects can result in the development of consequential late effects 
[2]. This temporal sequence of clinical changes observed following radiation exposure 
is assumed to reflect phenotypic differences between tissue systems of differing 
proliferative kinetics, broadly classified as early (fast) and late (slow) responding 
tissues. The pathogeneses of radiation effects in these tissues are also represented by 
different but not mutually exclusive mechanistic models of injury [3]. For example, 
although primary parenchymal cell injury is responsible for the development of most 
acute and late effects, damage to the surrounding vasculature is implicated in 
endarteritis obliterans and atherosclerosis, each responsible for secondary ischemic 
changes leading to tissue atrophy and fibrosis.
I.1.2 Cellular responses following irradiation of  early responding tissues
Although the pathological process of radiation-induced damage begins immediately 
after irradiation, the onset of frank clinical symptoms in tissues with rapidly 
proliferating cells such as epithelium of the skin and gastrointestinal tract is only 
apparent days to weeks later following exposure. This latency corresponds to the 
turnover duration of superficial differentiated epithelial cells in these early responding 
tissues, and effects are only observed when depleted progenitors in the deep proliferating 
layers fail to repopulate the superficial epithelium. In human skin, this loss of cells in 
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the basal layer which is dose-dependent, contributes to a dry or moist desquamatory 
response often associated with an erythematous reaction [4]. Following this early 
insult, a compensatory repopulation of the basal layer occurs and this is attributed to 
an increased proliferative capacity of surviving clonogenic cells within the irradiated 
area (Figure I.1) [5]. The accelerated repopulation of basal cells usually corresponds to 
the resolution of clinical symptoms approximately 50 days following initial insult [6]. 
In severe cases where significant losses of basal cells occur following a course of high 
dose irradiation, non-healing of moist desquamation can potentially progress to 
necrosis and consequential late effects in the skin [5].
Figure I.1 Changes in the basal cell population during a 6-week course of skin irradiation in 
which 2 Gy were given daily except weekends to a total dose of 60 Gy over 42 days. Reprinted 
from Archambeau et al., 1995 with permission [6].
Radiation responses of  normal tissues 3
Hypoplasia of the basal parenchyma as a precipitating mechanism for radiation-
induced acute effects occurs primarily through mitotic death or apoptosis of the 
progenitor cells. Following exposure to ionising radiation, mitotic death occurs as a 
result of residual chromosomal damage contributing to a loss of cell dividing capacity 
within the initial or subsequent few cycles of cell division [7, 8]. Apoptosis, on the 
other hand, follows a sequence of nuclear condensation, fragmentation, phagocytosis, 
degradation, and is dependent on the ataxia-telangiectasia mutated (ATM)-p53 
activation pathway, a key component of the DNA damage response (DDR) [9, 10]. 
Although it is widely assumed that mitotic death is the predominant mechanism of 
radiation-induced cell death in the majority of tissues, apoptosis has an unequivocal 
role in this aspect in certain cell and tissue types. For example, lymphocytes, serous 
cells of the salivary glands, and proliferating cells within the crypts of the gastrointestinal 
mucosa have a propensity to undergo apoptosis during interphase following irradiation 
[11–13]. More recently, the phenomenon of low dose hypersensitivity in basal cells 
of the human epidermis has been attributed to the induction of growth arrest and 
apoptosis [14]. Regardless of the mechanism, it is largely acknowledged that cell death 
following exposure to ionising radiation is often a direct consequence of an inability 
to repair DNA damage, in particular double-strand breaks (DSB), induced by the 
production of free radicals secondary to ionisation events within the cell nucleus 
[15–17].
Inflammatory responses relating to the activation of proteolytic enzymes and 
proinflammtory cytokines are also induced during the early phases following exposure 
to ionising radiation [18, 19]. Together with changes in the vasculature and vascular 
permeability, these processes are involved in the development of tissue inflammation, 
oedema, and recovery following irradiation. The implication of microvascular 
endothelial cell death as a precursor to subsequent induction of apoptosis in progenitor 
cells within the gastrointestinal mucosa further raises the possibility of a potential 
significance of vascular injury in the pathogenesis of acute effects, arguing against the 
conventional pathophysiological model of acute gastrointestinal syndrome [20].
I.1.3 Cellular responses relating to late radiation effects
Late effects are characteristic of damage in tissues containing lowly proliferating 
cellular elements, such as the spinal cord, brain, fatty tissue, and connective tissue. 
Effects are also diverse, ranging from fibrosis, atrophy to necrosis, with clinical 
progression and severity strongly dependent on overall radiation dose and fraction size 
[21]. Commonly, symptoms arise months to years after treatment with the potential to 
aggravate decades beyond initial onset in a subset of severely affected individuals [22]. 
This long latency to onset of clinical symptoms has historically been understood to 
reflect the prolonged cell cycle transition to mitosis, upon which slow proliferating 
stem cells harbouring residual DSB experience some form of mitotic catastrophe. In 
the instance of radiation-induced tissue atrophy, the loss of endothelial stem cells 
through the process of mitotic death or cellular senescence has been postulated as a 
contributory mechanism for parenchymal cell loss secondary to vascular injury [23].
For some cell types, cellular senescence may be an alternative fate to mitotic death 
in response to residual DNA damage. Stress-dependent replicative senescence is 
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associated with telomere shortening, and is induced in human fibroblasts by low levels 
of radiation-induced DSB [24]. After high therapeutic doses (≥60 Gy), cell replication 
is severely limited. In the absence of telomere shortening, human fibroblasts enter a 
phase of prolonged cell cycle arrest resembling senescence, sustained by the expression 
of p53, p21, and p16 [25, 26]. In the context of late fibrosis, the transformation of 
mitotic progenitor fibroblasts to a senescent post-mitotic fibrocyte lineage, induced 
through irradiation, is a key process in the pathogenesis of this late effect. It is well 
established that these post-mitotic fibrocytes are primarily responsible for the enhanced 
synthesis and deposition of extracellular matrix proteins leading to the development 
of radiation-induced fibrosis [27].
Included in the repertoire of cellular radiation responses are a series of paracrine 
and autocrine signalling events which in addition to the mechanisms of cellular death 
and senescence, play significant roles in the pathogenesis of late effects. Most notably, 
transforming growth factor β1 (TGFβ1) produced by a variety of inflammatory, 
endothelial, and epithelial cell types in response to irradiation, is one of the several 
cytokines including interleukin-13 (IL-13) and connective tissue growth factor (CTGF), 
responsible for the activation and expansion of myofibroblast progenitors during 
the early phases of fibrogenesis [28–30]. Unlike the other cytokines which are 
largely regulated through gene transcription, active TGFβ1 is released following the 
dissociation of a latency-associated peptide from its latent form, a process catalysed 
by proteases and reactive oxygen species generated after radiation exposure [31, 32]. 
Although it is unclear if these mentioned molecular and cellular processes activated 
days to weeks post-radiotherapy relate to complications manifesting months to 
decades later, the ability to ameliorate some of these late effects through selective 
inhibition of these pathways suggests that they are probably integral in the development 
of late effects [33, 34].
I.1.4 Determinants of  acute and late normal tissue responses
Acute and late radiation effects are mostly deterministic, with threshold doses 
dependent on a spectrum of confounding variables. Broadly, these can be classified 
under treatment-, organ-, or patient-related factors.
I.1.4.1 Treatment-related factors
Examples of treatment-related factors include total dose and dose per fraction, 
treatment volume, and the concurrent use of systemic therapy. The conventional 
wisdom of delivering a high total dose in small fractionated doses was based on the 
assumption that this would allow for maximal killing of tumour cells while sparing 
detrimental effects to normal tissues. This pragmatic approach was further supported 
by findings from early hypofractionation studies where increased rates of normal 
tissue toxicities were observed from the use of large fraction sizes without the necessary 
reduction of total treatment dose [35, 36]. From these early clinical studies and 
empirical radiobiological modelling, it became well established that late effects are 
generally more sensitive to fraction size and less sensitive to changes in overall treatment 
time compared to acute effects [37, 38]. Normal tissue responses are also heavily 
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dependent on total radiotherapy dose as evidenced by the steep dose-response curves 
derived for the onset of late effects, implying that a small change in dose is associated 
with large differences in toxicities (Figure I.2). This steep dose-response relationship 
was nicely illustrated in the results of the UK START Trial A, where based on indirect 
estimates generated from a comparison of normal tissue-related outcomes between 
different fractionation schedules in the treatment of early breast cancer, a 5.2% effect 
on late toxicities was estimated for every 2 Gy change in dose [39]. Separately, volume 
of irradiated tissue is also important, with larger volumes more likely to be susceptible 
to organ functional damage [40]. Finally, the addition of concurrent systemic therapy 
could also potentially exacerbate normal tissue effects since most chemotherapy 
agents work by inflicting cellular DNA damage to tumours and normal tissues alike 
[41].
I.1.4.2 Organ-related factors
Organ-specific factors relate to regional variability in radiosensitivity and hierarchical 
organisation of functional units (serial or parallel) within the organ. The importance 
of topographical heterogeneity of radiosensitivity within the organ can be illustrated 
by experimental observations of radiation-induced parotid gland dysfunction in 
animal models. As reported in rats, a differential effect on salivary production is 
observed between irradiation of the cranial and caudal ends of the gland, with the 
former being demarcated as the more radiosensitive region [44]. Similarly, in rat models 
of radiation-induced heart disease, volume irradiation including the atria of the heart 
resulted in cardiac failure at much lower doses than irradiation of the ventricles alone 
[45]. Tolerance of normal tissue is also dependent on the functional reserves and 
structural organisation of the organ. For example, large doses of radiation delivered to 
a small volume of the lung would be far less harmful as opposed to low dose irradiation 
Figure I.2 Cumulative frequency dose-response curves illustrating steep dose-gradients for 
late effects. The left (dotted) curve shows data for skin telangiectasia [22] and right (solid) 
curve is the putative dose-response curve for spinal cord necrosis [42]. Adapted from Barnett 
et al., 2009 with permission [43].
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to the whole lung. Conversely, a high dose to a small segment of the spinal cord could 
potentially harbour disastrous consequences whereas low doses to a long segment are 
largely innocuous.
I.1.4.3 Patient-related factors: Evidence for an intrinsic component in inter-
individual variability of normal tissue responses
Patient-related conditions including previous trauma/surgery to the irradiated site and 
co-morbidities, particularly those associated with impaired vascularity and connective 
tissue disorders, are potential modulators of radiation effects and wound recovery 
[46–48]. In the treatment of early breast cancer, the presence of patient co-morbidities 
such as post-operative breast oedema or hematoma in the setting of high radiotherapy 
doses significantly influenced the risk of late skin fibrosis [49]. Nonetheless, despite 
robust control of these treatment- and patient-related variables, as much as 70% 
of variance in acute and late normal tissue responses between individuals are still 
unaccounted for [50]. Similarly, observations of acute skin erythema and late 
telangiectasia in breast radiotherapy patients, having received the same radiation 
doses and fractionation schedules, revealed significant inter-individual variation in the 
progression and severity of clinical effects [51, 52]. Collectively, these findings provide 
supportive evidence to suggest that wide differences in normal tissue responses 
between individuals are likely due to inter-individual differences in intrinsic 
radiosensitivity.
The evidence for an intrinsic determinant of normal tissue radiosensitivity dates 
back to the seminal discovery of the ataxia-telangiectasia (A-T) radiosensitive 
phenotype [53]. Although severe clinical reactions following radiotherapy and elevated 
levels of chromosomal damage induced by radiation were observed in patients with 
this genetic defect [54, 55], it was the seminal finding illustrating the increased 
radiosensitivity of fibroblast and lymphoblastoid cell lines derived from these 
patients that provided a direct correlation between genetic susceptibility and clinical 
radiosensitivity. Since then, through a variety of screening approaches, a number of 
genetic syndromes, mostly associated with a DDR or DSB repair defect, have been 
linked to a clinically radiosensitive phenotype (Table I.1). However, intrinsic sources of 
the wide differences in normal tissue radiosensitivity between non-syndromic 
individuals remain largely unknown, although high frequency, low penetrance allelic 
variation and epigenetic modifications have been proposed as possible pathways [43, 
56]. Regardless of the genetic or epigenetic source, the concept of a significant intrinsic 
modulator of normal tissue radiosensitivity proposes the notion that intrinsic 
radiosensitivity of target cells involved in the cellular processes of early and late effects 
are perhaps indicative of clinical response in normal tissues after radiotherapy, thereby 
providing the rationale for a predictive assay of normal tissue radiosensitivity.
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I.2 PREDICTING NORMAL TISSUE RADIOSENSITIVITY
I.2.1 Clinical value of  predicting intrinsic normal tissue radiosensitivity
Intuitively, the idea of having an assay capable of estimating normal tissue 
radiosensitivity in a specific patient seems highly appealing. Referring to the proven 
benefit of improved tumour control with the use of escalated radiotherapy doses in 
prostate cancers, a possible strategy where predictive testing for normal tissue 
radiosensitivity could be exploited would be to identify the sensitive tail of the normal 
distribution of intrinsic radiosensitivities, subjecting these individuals to the 
conventional or even a reduced dose while treating the remainder with higher doses. 
This manner of stratifying treatment options as illustrated in Figure I.3, should in 
theory maintain the overall incidence of normal tissue toxicities and improve 
therapeutic ratio [61]. Other potential approaches pertaining to the implementation 
of a predictive assay for normal tissue radiosensitivity include 1) screening for rare 
individuals with extreme radiosensitivity, treating these cases with a reduced total dose 
[62, 63], and 2) individualising radiotherapy doses based on the derived in vitro cellular 
radiosensitivity of each individual such that patients receive an isoeffective treatment 
with equal likelihood of normal tissue toxicities [64]. Judging from these possible 
approaches, the clinical benefits of such an assay are self-evident, but the main hurdle 
remains establishing a reliable and reproducible in vitro assay that is actually clinically 
applicable. In spite of the confronted challenges to develop a robust assay, the fact that 
at least 20% of patients are affected by moderate to marked chronic adverse events 
following radiotherapy reiterates the importance to address this unmet clinical need 
Table I.1 Defective DDR/DSB repair syndromes associated with clinical 
radiosensitivity [57].
Syndrome Protein
Ataxia-Telangiectasia (A-T) ATM
A-T-like Disorder (ATLD) MRE11
Nijmegen Breakage Syndrome (NBS) NBS1
Rad50 defective patient Rad50
LIG4 syndrome Ligase4
RIDDLE syndrome [58] RNF168
RS-SCID Artemis deficient
Artemis over-expressed patients (84BR, 175BR cell lines) 
[59]
Artemis over-
expression
DNA-dependent protein kinase (DNA-PK) exon deletion 
in a patient with xeroderma pigmentosum [60]
DNA-PK
Abbreviations = MRE11, meiotic recombination element 11; LIG4, Ligase 4; RS-SCID, 
radiosensitive-severe combined immunodeficiency.
8 Introduction
[39, 49]. As a sign of interest on this issue, a global collaborative effort was recently 
initiated to investigate the suitability of single nucleotide polymorphisms as surrogate 
markers of normal tissue radiosensitivity [65].
I.2.2 Biological considerations for predictive assays of  radiosensitivity
I.2.2.1 In vitro cellular radiosensitivity as a biomarker of clinical response to 
radiotherapy
Early evidence for a linkage between intrinsic cellular radiosensitivity and normal 
tissue responses arose from experimental observations of a correlation between in 
vitro cellular radiosensitivity and clinical phenotype in individuals with rare genetic 
syndromes. As demonstrated in patients with A-T, germline mutations in the ATM 
gene resulting in a defective protein and consequential lack of a robust DDR, 
contributed to an increased radiosensitivity observed in all cells and tissues [62, 66, 67]. 
Further support for this idea is found in reports describing an increased in vitro 
radiosensitivity of fibroblasts in non-syndromic patients with an abnormally severe 
reaction to radiotherapy [68, 69].
Cellular radiosensitivity is often referred to by the clonogenic potential of a cell 
following exposure to ionising radiation and is measured using the colony forming 
assay (Figure I.4). To date, assessment of colony forming ability remains widely 
regarded as the method of choice for determination of mitotic death, a cellular 
Figure I.3 Example of a dose stratification strategy based on intrinsic radiosensitivity of 
breast radiotherapy patients with late telangiectasia as the clinical end-point for normal tissue 
effect. Cumulative frequency curves of telangiectasia for patients are stratified into three 
sub-groups of radiosensitivity. (A) represents the most sensitive individuals while (B & C) 
represent the intermediate and most ‘resistant’ groups, respectively. Solid line indicates overall 
cumulative frequency for the whole cohort, generated based on data from the Gothenburg 
breast radiotherapy studies [21]. From this curve, it is estimated that overall incidence of skin 
effects is 10% after 48 Gy. To maintain a similar incidence of toxicities, doses can be reduced 
in patients of group A while patients in groups B and C can afford to receive a higher dose, 
albeit to a lesser degree in group B. Reprinted with permission from Burnet et al., 1996 [61].
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response many consider to be indicative of the effectiveness of radiation-induced cell 
killing. Standard protocols define a colony to consist of at least 50 cells, thereby 
implying that the surviving progeny had undergone at least five cycles of cell division, 
an appropriate cut-off considering that cells are still capable of dividing beyond the 
initial cycle in the presence of chromosomal damage [8]. Using this assay, in vitro 
radiosensitivity is typically expressed as a function of the number of surviving 
progenies after a 2 Gy dose (SF2). Alternatively, D0 and D0.1 which refer to the dose 
required to reduce surviving fraction (SF) to 0.37 and 0.1, respectively, are also 
commonly adopted parameters of cellular radiosensitivity. Illustrative definitions of 
these parameters are provided in Figure I.4 (Right panel).
In spite of concerns regarding the practicality of the colony forming assay in the 
clinical setting, initial series of case-control studies applying this assay for the 
estimation of in vitro cellular radiosensitivity reported promising results suggestive of 
a relationship between in vitro cellular and in vivo normal tissue responses among 
non-syndromic individuals [71–77]. These studies were designed based on the 
hypothesis that loss of cellular ‘reproductive’ ability or otherwise, known as mitotic 
death, is the predominant cellar response contributing to the pathology of most acute 
and late adverse events following radiotherapy. In the instances of epithelial 
desquamation and tissue atrophy, an association with loss of clonogenicity in 
parenchymal cells would be plausible. However, as pointed out earlier, cellular 
Figure I.4 (Left panel) Clonogenic assay performed using clones of SW-1573 lung tumour 
cells. Upper panel represents untreated controls with 70 (left) and 115 (right) colonies after 
seeding 100 and 200 cells, respectively. Lower panel shows effects of 4 Gy irradiation in reducing 
colony forming ability after seeding 400 (left) and 800 (right) cells. Adapted from Franken et 
al., 2006 with permission [70]. (Right panel) Survival curve of CNE-1 nasopharyngeal  tumour 
cells after irradiation. SF is derived using the following formula: SF = number of colonies 
formed after irradiation/(number of seeded cells x plating efficiency). SF2 is indicated by the 
extrapolated dotted line on the y-axis while the solid line indicates the manner by which D0.1 
is derived.
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responses other than mitotic death such as senescence, lethal cell cycle arrest, and 
terminal differentiation may also be relevant to tissue responses like fibrosis [27, 30]. 
Nonetheless, in these studies, in vitro clonogenic potential of irradiated primary 
fibroblasts or lymphocytes isolated from skin biopsies and peripheral blood samples, 
respectively, were revealed to correlate with a range of acute and late effects, mostly 
in the human skin. Of greater interest, even though fibroblasts are not the primary 
target cells responsible for the onset of telangiectasia or acute skin erythema and 
desquamation, in vitro clonogenecity of this cell type was found to be associated with 
clinical severity of these late and early clinical end-points, respectively [71–73, 76]. In 
the same vein, cellular radiosensitivity of lymphocytes was also correlated with acute 
and late effects in the skin and pelvis, although the relevance of this cell type in the 
pathology of these normal tissue effects is largely unknown [77, 78]. Conceptually, 
these findings allude to a model where factors generic in all cells and tissues modulate 
radiation responses within an individual. If indeed intrinsic host factors were the main 
determinants of normal tissue effects, it would be logical to expect different cells and 
tissues within an individual (host) to share a similar radiosensitivity phenotype, 
implying then that radiosensitivity assays performed using different cellular systems 
should theoretically yield similar predictive power. With the added advantage of tissue 
accessibility and experimental practicality, these findings provided the scientific 
basis justifying the use of lymphocyte-based assays in predicting normal tissue 
radiosensitivity, despite suggestions of clinical and laboratory data contradictory to 
this model.
I.2.2.2 Inter-cell/tissue variation in cellular and clinical radiosensitivity
The model of a dominant intrinsic component of normal tissue radiosensitivity, 
though supported by the phenotypes of rare genetic syndromes, remains inconclusive 
in non-syndromic individuals. For example, although in vitro cellular radiosensitivity 
of fibroblasts and lymphocytes have been shown to be independently predictive of 
normal tissue responses among radiotherapy patients, a lack of correlation of in vitro 
radiosensitivity between these cell types has also been reported, thus questioning if 
cellular radiosensitivity of one cell type is representative of sensitivity of any other 
within the same individual [67, 74, 79, 80]. The relationship between different late 
effects in the same tissue was also examined in patients who received post-mastectomy 
radiotherapy to the chest wall and axilla. Although a significant intrinsic host factor 
was identified for a specific clinical end-point, severities of unrelated clinical end-
points of late skin telangiectasia and fibrosis were not correlated in the same patients, 
suggesting that perhaps in non-syndromic individuals, radiation responses in different 
tissues are not dominated by a common intrinsic pathway [81]. However, there are 
caveats pertaining to the conclusions of this study. Firstly, it is generally harder to grade 
for varying degrees of late fibrosis given that it is a more subjective change relative to 
telangiectasia. Secondly, the study reported considerable inter-individual differences 
for telangiectasia, but contrastingly, scores for fibrosis were largely comparable 
between patients. Although it would seem intuitive that these late effects are not 
related, in truth, not a lot of clinical information is available from this study on fibrosis 
as a clinical end-point. Given the wider implications of these laboratory and clinical 
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findings, it is still at present unclear if predictive assays of radiosensitivity should 
be designed aimed at a specific tissue or clinical end-point. Nonetheless, utilising a 
lymphocyte-based predictive assay of clinical radiosensitivity remains a sensible 
approach as supported by findings of more recent studies indicating an association 
between radiation-induced cellular responses in lymphocytes and clinical radio-
sensitivity in a range of normal tissues [82–86].
I.2.2.3 Association between normal tissue and tumour radiosensitivity
Separately, it has been suggested that a predictive assay for normal tissue radiosensitivity 
may also be extrapolated to estimating tumour response to irradiation. The background 
of this proposed relationship lies in the notion that tumour cells likely retain the 
radiosensitivity of their tissues of origin, and hence an association between radio-
sensitivity of normal tissue and tumour is in theory possible. Early evidence in support 
of this notion was largely derived from experimental findings in mouse and human 
cell lines. In the former, comparative analyses of in vitro and in vivo radiosensitivity 
between the RS-SCID and control mouse models indicated an increased response 
to ionising radiation in tumours and normal tissues of the RS-SCID phenotype 
compared to control [87]. Complementing the findings in mice, evaluation of in vitro 
radiosensitivity of tumour and fibroblast cell lines derived from the same patients 
revealed an intra-individual association between both cell types [88]. To validate the 
laboratory findings in mice and human cells, a correlation analysis of local tumour 
control and normal tissue complications was performed in head and neck cancer 
patients treated radically with institutional standardised radiotherapy protocols [89]. 
Although a study design of such nature is unavoidably inherent with statistical biases 
and treatment-related confounders, nonetheless these investigators reported an 
associative trend between tumour control and acute normal tissue complications. In a 
separate study of cervical cancer patients treated radically with radiotherapy, in vitro 
radiosensitivities of tumour cells and lymphocytes of these patients were found to be 
independently predictive of late radiotherapy morbidities [90]. If indeed related, the 
association between tumour and normal tissue radio sensitivity indirectly proposes a 
significant clinical value for a predictive assay of the latter. For example, in individuals 
identified to be intrinsically radiosensitive, a reduction in radiotherapy dose would 
reduce the probability of complications without necessarily diminishing the chances 
of cure [91].
I.2.3 Assays for predicting normal tissue radiosensitivity
As mentioned above, the early assays of cellular radiosensitivity tested for their 
predictive value of normal tissue responses were primarily colony forming assays 
performed mostly in fibroblasts or lymphocytes isolated from skin biopsies or 
peripheral blood samples of patients, respectively. Using this assay, there is a reasonable 
amount of evidence to suggest that in vitro cellular radiosensitivities of these cell types 
are indicative of in vivo normal tissue responses following radiotherapy. However, 
testing of cellular clonogenic ability is slow, labour intensive, and requires a high level 
of expertise rendering it unsuitable for routine clinical use. Hence, other alternative 
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cellular end-points related to loss of clonogenecity have been considered and tested in 
case-control studies of predicting normal tissue radiosensitivity. Among them, assays 
of chromosomal aberration frequency, DNA damage, and radiation-induced apoptosis 
are few which have demonstrated a certain level of correlation with in vivo normal 
tissue responses.
I.2.4 Chromosomal radiosensitivity assays
I.2.4.1 Correlation between chromosomal damage and cell survival
The mechanistic linkage between chromosomal aberration and cell survival has long 
been well appreciated. Apart from the early experimental findings by Dewey et al. 
implicating the lethal effects of ionising radiation to structural damage of the 
chromatin [7], further evidence for a causative relationship between chromosomal 
damage and radiation-induced cell death, specifically in the form of a mitotic 
catastrophe, was contributed by elegant experiments conducted in live cultured 
mammalian cells. In these reports by Grote et al. and Joshi et al., presence of acentric 
fragments during mitosis resulted in a loss of proliferation in as many as 80% of 
cells with the remaining 20% not progressing beyond a further five cycles [92, 93]. 
Nonetheless, it has also been opined that the effects of radiation-induced cell killing 
may not be fully explained by the induction of exchange and deletion type aberrations. 
As reported in a range of rodent tumour cell lines, the induction of dicentrics, centric 
rings, and acentric fragments failed to account for the overall proportion of inactivated 
clones following exposure to different sources of ionising radiation, suggesting that 
perhaps other forms of cellular damage may play an important role in radiation-
induced cell killing [94]. In contrast, it was reported in human and rodent fibroblasts 
that following irradiation, the proportion of cells without lethal chromosomal 
aberrations corresponded closely to surviving fraction [95, 96]. It is probable that this 
variation in experimental findings is attributed to differences in physiological 
characteristics between individual cell types. As evident in the analysis of surviving 
fraction and chromosomal aberration frequencies in irradiated human lymphocytes, a 
correlation between chromosomal damage and surviving fraction was only observed 
after adjusting for the loss of cells occurring through interphase cell death, a 
mechanistically distinct pathway of cellular demise common in certain cell types [97]. 
In summary, there is conclusive evidence indicating a direct association between 
structural chromosomal damage and cellular radiosensitivity in most, if not all, 
cellular systems, hence justifying the use of chromosomal aberration frequency as an 
alternative indirect marker of cellular radiosensitivity.
I.2.4.2 In vitro chromosomal radiosensitivity as a predictive marker of normal tissue 
responses after radiotherapy
Chromosomal aberrations detected using the micronucleus and conventional fixed 
metaphase assays in irradiated lymphocytes have been shown to correlate with normal 
tissue radiosensitivity in radiotherapy patients. Specific to chromosomal but not 
chromatid-type damage, lethal aberrations namely exchanges (dicentrics, centric 
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rings) and deletions (acentric fragments) are identified using these techniques (Figure 
I.5). Early evidence suggestive of a relationship between chromosomal and clinical 
radiosensitivity was observed in breast cancer patients suffering from severe radio-
therapy-induced reactions. Using both micronucleus and metaphase assays, these 
clinical over-reactors were found to have yields of micronuclei and dicentrics in 
irradiated lymphocytes which were comparable to A-T heterozygotes [98], indirectly 
suggesting that clinically radiosensitive breast cancer patients are potential carriers of 
the A-T gene. Although the validity of the latter hypothesis remains questionable given 
that subsequent genomic analysis of primary cells obtained from small cohorts of 
over-reactors to radiotherapy had failed to reveal the presence of mutations in ATM or 
other DDR-related genes [84, 99], nonetheless applying a novel method of stratifying 
patients according to their in vitro chromosomal radiosensitivity phenotype (Figure 
I.6), it was demonstrated rather convincingly in more recent case-control studies that 
this cellular parameter can be applied as a potential predictor of radiotherapy-induced 
normal tissue effects [84–86].
I.2.5 Assays of  DNA damage responses
I.2.5.1 Overview of cellular responses related to ionising radiation-induced DNA 
damage
Following exposure to ionising radiation, exogenous free radicals produced through a 
series of ionisation events within the tissue are a major contribution to DNA damage 
within the cell nucleus. Among the array of DNA lesions induced by ionising radiation, 
Figure I.5 (Left) Metaphase spread prepared using conventional techniques illustrating 
exchanges (closed symbols) and deletions (open symbols). (Right) Example of a micronucleus 
seen in the bi-nucleate cell on the left. Micronuclei are representative of acentric fragments 
or lagging chromosomes formed during anaphase which are not included in the nuclei of the 
daughter cells. Courtesy of Dr. Jayne Moquet for the micronucleus image.
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it is generally agreed that DSB are the most lethal. It is therefore paramount that cells 
repair DSB accurately as failure to do so can result in mutations or genetic 
rearrangements, and indeed, a single DSB is sufficient to disrupt the genomic integrity 
and kill a cell [100, 101]. In response to the induction of a DSB, a complex and co-
ordinated set of signalling pathways involving DNA damage sensing, cell cycle arrest, 
repair, and cell death is triggered within the cell. This chain of events is often collectively 
termed as the DDR (Figure I.7).
One of the key aspects of these DNA damage signalling events includes the inhibition 
of cell cycle progression while damage persists, so as to prevent the replication of 
damaged DNA or segregation of damaged chromosomes during mitosis. ATM, a 
member of the phosphatidylinositol 3-kinase-related kinases (PI3KK) superfamily, 
plays a central role in mediating these responses following its recruitment to DSB sites 
by the MRN complex, comprising of MRE11, Rad50, and NBS1 [103, 104]. A key 
substrate for ATM is the histone 2A variant (H2AX) which, upon phosphorylation, 
leads to the formation of γH2AX foci [105]. Phosphorylation of H2AX contributes to 
the recruitment of mediator and additional damage response proteins, such as 
mediator of DNA damage checkpoint protein 1 (MDC1) and tumour suppressor p53 
binding protein 1 (53BP1), to DSB sites [106]. Additionally, amplification of the DDR 
signal occurs through MDC1-mediated accumulation of ATM at these sites of 
damage, facilitating further phosphorylation of H2AX [107]. Pertinent to the 
Figure I.6 Association between chromosomal radiosensitivity (acentric fragments) and 
grade 2 or 3 fibrosis in breast cancer patients ascertained using the log rank test. Patients 
were stratified according to their in vitro chromosomal radiosensitivity, as opposed to clinical 
phenotype. High sensitivity, ≥ Mean + 1 SD lethal aberrations per lymphocyte after 6 Gy; low/
intermediate, < Mean + 1 SD; mean = 5.47, SD = 0.71. SD = standard deviation. Adopted with 
permission from Hoeller et al., 2003 [86].
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regulation of cell cycle checkpoint, activation of ATM leads to the downstream 
phosphorylation of checkpoint kinase 2 (Chk2) and p53 [108]. While Chk2 functions 
mainly via its subsequent phosphorylation of cell division cycle 25 (Cdc25) 
phosphatases, p53 is involved in the transcriptional regulation of p21, a cyclin-
dependent kinase (Cdk) inhibitor which modulates G1/S checkpoint arrest. Likewise, 
ATM-mediated activation of Chk2 and p53 also function redundantly in the induction 
of apoptosis as a response to unrepaired radiation-induced DNA damage. Perhaps, of 
Figure I.7 Schematic representation of how cells respond to DSB. The presence of DSB is 
recognised by various sensor proteins which in turn initiate a range of downstream signalling 
pathways that impact a wide variety of cellular processes. Reused with permission from 
Jackson, 2009 [102].
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a greater significance to cellular radiosensitivity, it has been proposed that ATM is 
required for the repair of approximately 15% of DSB induced by ionising radiation 
[109]. More recently, mechanistic insights on this ATM-dependent DSB repair indicate 
that these breaks likely represent damage within the heterochromatin and ATM 
signalling via KRAB-associated protein 1 (Kap1) overcomes the barrier to DSB repair 
posed by the more condensed heterochromatin structure [110, 111]. Figure I.8 provides 
a schematic representation of the recruitment of ATM and ATM-related proteins at 
DSB sites and their roles in modulating checkpoint control during various phases of 
the cell cycle.
It is evident from the above mentioned molecular pathways that the prime objective 
for cells experiencing DSB is to initiate a series of cellular responses conducive for the 
repair of these toxic lesions. In higher eukaryocytes, DSB repair is known to occur via 
two largely distinct and complementary pathways, namely non-homologous end-
joining (NHEJ) and homologous recombination (HR) [115]. Whilst NHEJ remains 
the primary mechanism of DSB repair in most circumstances, HR plays a significant 
role in repair during S and G2 phases of the cell cycle [116]. Given their relevance to the 
discussion of this thesis, these DSB repair pathways are further elaborated in the 
following section.
I.2.5.2 NHEJ and HR in the repair of ionising radiation-induced DSB
NHEJ, as mentioned above, represents the major DSB repair pathway in mammalian 
cells. Minutes after the induction of DSB, repair takes place primarily via end-joining 
while other damage signalling processes relating to checkpoint control, onset of 
apoptosis, and chromatin remodelling initiate simultaneously in the background 
[117]. The core proteins involved in NHEJ include the Ku sub-units, DNA-PK, LIG4, 
and its co-factor, X-ray cross complementation group 4 (XRCC4). Together with the 
MRN complex, Ku70/80 are among the earliest factors rapidly recruited to the ends of 
DSB [118]. This is soon followed by binding of DNA-PK, generating the DNA-PK 
holoenzyme complex resulting in activation of its kinase activity [119]. Broken ends of 
DNA are then acted upon by nucleases, most notably, Artemis, before being ligated by 
the XRCC4-like factor (XLF)-XRCC4-LIG4 complex [120, 121]. Interestingly, in 
contrast to defects in other NHEJ core proteins, Artemis-defective cells continue to 
repair most DSB efficiently which may suggest that Artemis-dependent end-processing 
is not an integral step in NHEJ [122]. Recent evidence however revealed that Artemis 
is required in the repair of a small subset of DSB (≈ 15%) and current thinking points 
to a role for Artemis in the end-processing of breaks located within the heterochromatin 
[109, 123].
Unlike in NHEJ, initial resection of DSB ends is mandatory in HR, and remains an 
important regulatory step in the choice between both pathways for the repair of DSB. 
This resection process is performed by the MRN complex, in conjunction with 
auxiliary factors, such as C-terminal binding protein interacting protein (CtIP), RECQ 
family helicases, exonuclease 1 (Exo1), and Dna2 [124–126]. The resulting single 
strand DNA (ssDNA) overhangs are then coated by ssDNA binding complex replication 
protein A (RPA) before being replaced by RAD51, promoting invasion of a homologous 
template on the sister chromatid strand [127]. This need for a homologous template 
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Figure I.8 (Top) ATM activation is initiated by the recruitment of  MRN to sites of DSB. 
ATM is also recruited to the flanks of the break where at these flanking sites, ATM is partially 
activated and phosphorylates p53 along with other substrates. Acetylation also contributes 
to the activation process of ATM. MDC1 plays a central role in protein assembly at DSB 
sites. It binds γH2AX, NBS1, and recruits RNF8, an E3 ubiquitin ligase which catalyses the 
ubiquitylation of H2A-type histones, promoting the recruitment of 53BP1 to the site of DSB 
[112, 113]. RNF168, also an ubiquitin ligase, amplifies this ubiquitylation process and stabilises 
the DDR protein complex [58, 114]. Adapted with permission from Jeggo et al., 2009 [57]. 
(Bottom) ATM regulation of checkpoint arrest at different phases of the cell cycle. Arrows 
indicate stimulation; T-shape lines mark inhibition; inhibitory phosphorylations are indicated 
by a line through the arrow. The numbers indicate the positions of the phosphorylated residues. 
Reprinted with permission from Shiloh, 2003 [10].
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also explains the availability of HR only during S and G2 phases of the cell cycle. The 
search for homology and strand invasion is largely assisted by a protein complex 
comprising of XRCC2, XRCC3, Rad52, Rad54, Rad51 paralogs b, c, d, breast cancer 
1 and 2 (BRCA1, BRCA2) [128]. Following DNA synthesis and ligation by DNA 
polymerases and ligase 1, respectively, DNA helicase and resolvase enzymes then 
mediate cleavage and resolution of HR intermediates to yield intact, repaired DNA. 
Judging from the processes in HR, it is evident that compared to NHEJ which is prone 
to erroneous repair, HR repairs DSB with a greater degree of fidelity. A schematic 
illustration of both repair pathways is provided in Figure I.9.
I.2.5.3 Biological principles underlying the association between in vitro DNA 
damage responses and normal tissue radiosensitivity
The ability to repair DSB is imperative for cell survival as evidenced by the increased 
radiosensitivity observed in cells of syndromic individuals harbouring an intrinsic 
Figure I.9 (A) NHEJ, (B) HR. See main text for details of the individual pathways. Reprinted 
with permission from Downs et al., 2007 [129].
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DSB repair defect [130, 131]. Among non-syndromic patients displaying significant 
inter-individual variation in DSB repair, a similar association was also observed 
between residual DSB levels and loss of clonogenicity, confirming once again that these 
cellular responses are related [15, 132–134]. These findings led to the interpretation 
that assays of DNA damage may be a sensible alternative to the more cumbersome 
colony forming assay for predicting normal tissue radiosensitivity [61]. Early methods 
for measuring DNA damage were predominantly based on pulsed field electrophoresis 
or the comet assay. In more recent times, the discovery of damage-induced foci 
formation at DSB sites such as γH2AX and 53BP1 along with their close correlation 
with DSB repair kinetics has led to their progressive implementation as surrogate 
markers of DSB [135, 136]. To date, clinical and experimental findings arising from a 
number of small case-control studies as well as mouse models have suggested a 
promising correlation between residual DNA damage and normal tissue radiosensitivity, 
regardless of the DNA damage assay being applied [137–142]. Of interest, high levels 
of residual DSB following irradiation and repair in human fibroblasts and blood 
lymphocytes were observed in individuals presenting with severe acute and/or chronic 
effects of radiotherapy [137–140]. The presence of residual DNA damage late into 
repair may hold mechanistic significance, particularly in the pathogenesis of normal 
tissue injury following fractionated radiotherapy. In the therapeutic setting where 
radiation is conventionally delivered in small equal daily doses over a protracted 
period, unrepaired genomic damage prior to the next fraction could lead to further 
accumulation of damage with each additional fraction, a phenomenon well docu-
mented in studies of fractionated irradiation in a number of tumour and normal tissue 
cell lines [143, 144]. It is therefore likely that subtle impairments of DNA repair could 
amount to exceedingly high levels of cellular genomic damage following repeated 
radiotherapy fractions, thereby potentially having a profound impact on subsequent 
cell fate and normal tissue responses. On the basis of this notion, it would be within 
reason to propose an association between intrinsically defined DNA repair capacity 
and normal tissue radiosensitivity of an individual.
Radiation-induced apoptosis appears to be another promising cellular marker 
associated with clinical radiosensitivity. By quantifying the levels of apoptosis in blood 
lymphocytes following in vitro irradiation, investigators have reported that low levels 
of apoptosis are indicative of overt clinical radiosensitivity, while high levels of 
apoptosis are specific for normal responders to radiotherapy (Figure I.10) [82, 83, 145–
147]. As illustrated in Figure I.11, considering that apoptosis is primarily an ATM-
mediated cellular response to ionising radiation, these findings could be interpreted to 
fit the A-T phenotype, where impaired apoptotic response and clinical radiosensitivity 
are both characteristic features associated with a loss of ATM function [147]. In 
further support of this notion, a recent quantification of ATM protein levels within a 
cohort of non-syndromic breast radiotherapy patients demonstrated an association 
between low levels of ATM and clinical radiosensitivity [148]. Although the mechanistic 
basis of increased cellular and clinical radiosensitivity among patients harbouring the 
A-T phenotype remains uncertain, lately, the inability to repair DSB located within the 
heterochromatin has been postulated to be a contributing factor [110, 111]. Judging 
from the clinical data presented in the studies demonstrating an association between 
apoptosis induction in irradiated lymphocytes and late adverse effects following 
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radiotherapy, it is likely that other mechanistic models besides A-T may account for 
the relationship between these cellular and clinical end-points. For example, decreased 
levels of apoptosis in patients with marked adverse effects could reflect an impaired 
response mechanism to cellular injury. Separately, it has also been proposed that 
Figure I.10 Cumulative incidence of grade ≥ 2 late adverse effects according to percentage 
of CD8 T-lymphocyte apoptosis 48 hours after 8 Gy in vitro exposure. Upper solid curve, 
≤ 16% apoptosis; middle dashed, 16-24%; lower dashed, > 24%. From Ozsahin et al., 2005 
with permission [83].
Figure I.11 Apoptotic responses of CD8 and CD4 T-lymphocytes from three cohorts 
of donors. +, 105 normal donors and 48 radiotherapy patients without late effects; •, 12 
radiotherapy patients with late effects; ×, 9 A-T homozygotes. Data are presented as z-scores 
(number of standard deviations from the mean). Note that patients with adverse effects tend to 
have lower than average z-scores. From Crompton et al., 1999 with permission [147].
References 21
apoptotic cells possess the ability to suppress pro-inflammatory signals associated 
with tissue injury provoked by radiation exposure [149, 150]. In these models, the 
relative association between radiation-induced apoptosis and normal tissue 
radiosensitivity as reported in these studies would be expected.
A comprehensive review of current literature indicates that there are now a range 
of possible assays for predicting risks of normal tissue effects in radiotherapy 
patients. As already elaborated, the scientific hypotheses underlying these assays are 
distinct but not mutually exclusive. In this background, an interesting approach to 
predicting normal tissue radiosensitivity could entail testing a combination of these 
assays in a cohort of radiotherapy patients presenting with varying degrees of 
normal tissue injury. In addition to comparing the robustness of each assay in 
predicting clinical response, a study of such nature also offers potential insights into 
the common molecular pathways between cellular and tissue responses following 
exposure to ionising radiation. For example, current evidence collectively indicates 
that molecular processes relating to DNA repair and induction of apoptosis may be 
impaired in clinically radiosensitive individuals [82, 83, 138-141, 145–147]. In this 
scenario, ATM functionality can be interpreted to be a central determinant of 
normal tissue injury following radiation exposure, even among non-syndromic 
individuals, since ATM shares critical roles in both DNA repair and apoptosis 
induction [10, 109–111].
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Project overview
II.1 BACKGROUND
As reviewed in the preceding chapter, there is clear evidence to support the notion of 
an intrinsic determinant of normal tissue radiosensitivity. Over the years, it has 
therefore been the interest of several research groups to establish in vitro cellular 
markers which are indicative of radiosensitivity of cells/tissues and consequently, 
predicts for normal tissue responses following curative radiotherapy. To date, colony 
forming assay remains the gold standard for assessing cellular radiosensitivity, but 
owing to its time consuming nature, surrogates assays have been investigated. These 
include assays of chromosomal and DNA damage, and between the different assays, 
there are modest levels of correlation with colony formation.
At first glance, early evidence arising from small case-control studies testing these 
assays to predict for normal tissue radiosensitivity appeared promising. Comparing 
the in vitro radiosensitivity of cells from carefully selected clinically radiosensitive 
individuals against those of matched controls, an apparent disparity in cellular 
responses to radiation exposure was evident between patients presenting with differing 
degrees of normal tissue effects after radiotherapy. Nonetheless, when a similar 
hypothesis was extrapolated to larger patient cohorts, results from these wider 
comparisons have mostly been inconclusive, prompting suggestions that these assays 
may not be clinically applicable for stratifying radiotherapy patients and perhaps more 
robust new methods should be sought. On this note, it is appropriate to highlight that a 
number of other key factors are also contributory to the outcomes of studies testing for 
predictive assays of normal tissue radiosensitivity. Broadly, these factors relate to patient 
selection and biological principles underlying the design of these predictive assays.
II.1.1 Clinical considerations in the selection of  ‘over-responders’ and ‘controls’
The ability to demonstrate an association between results of an in vitro radiosensitivity 
assay and the degree of normal tissue damage relies significantly on the accurate 
identification of clinical phenotype. Although it may not be possible to fully ascertain 
that the clinical severity of normal tissue effects truly reflects the intrinsic radiosensitivity 
of an individual, nonetheless clinical parameters that could influence normal tissue 
response, such as radiation dose, fraction size, the addition of systemic therapy as a 
radiosensitising agent, have to be considered during patient stratification. Secondly, 
the duration of follow-up could also affect the relative relationship between cellular 
and clinical end-points. Based on the work by Jung and colleagues, it is well characterised 
that the incidence of late effects in several organs occurs with exponential kinetics, and 
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in some individuals, these effects may only manifest years after radiotherapy [1]. 
Conversely, individuals presenting early on with late effects do not necessarily imply 
clinical radiosensitivity. On this basis, it may be prudent to test the chosen cohorts of 
‘over-responders’ and ‘controls’ for their rates of developing late tissue effects using 
the log-linear plots proposed by Jung et al. to confirm that they are indeed phenotypically 
distinct prior to testing of predictive markers.
Ideally, investigations into the efficacy of an in vitro cellular assay to predict for 
normal tissue radiosensitivity should preferably include homogenously treated 
patients with accurate documentation of treatment-related parameters relevant to the 
normal tissue of interest. The clinical end-point should be amendable to accurate 
assessment using a well established method of scoring, and should also have a 
component of significant inter-individual variation [2]. For reasons provided above, 
patients should also have consistent follow-up periods to ensure that their clinical 
ranking corresponds to the assigned phenotype [3]. Finally, factors other than the 
cellular parameter being tested that are known to influence normal tissue responses 
should be incorporated into a multivariate analysis, but in reality, this is often limited 
by the small scale of these studies given the low prevalence of clinically radiosensitive 
individuals.
II.1.2 Are cell-based assays valid systems for predicting normal tissue 
radiosensitivity?
Pertaining to the design of a predictive assay of normal tissue radiosensitivity, a 
frequently challenged notion revolves around choosing an ideal cellular system for a 
predictive assay. The idea for a cell- and tissue-specific approach to predictive assays of 
normal tissue radiosensitivity was initially put forth in the background of clinical 
evidence indicating a lack of association between the severity of different normal 
tissue effects within an individual, therefore proposing that perhaps predictive assays 
should be designed aimed at a specific tissue/clinical end-point [4–6]. Further support 
for this idea can be derived separately from laboratory data showing that radio-
sensitivities of different cell types within the same host are not necessarily correlated, 
indirectly implying that depending on the choice of cell-based assay, predictive 
potential of normal tissue radiosensitivity may differ [7–9]. However, arguing against 
this concept, positive outcomes have been observed in studies using either fibroblasts 
or lymphocytes to test for biomarkers of radiosensitivity in a range of normal tissues, 
but again, the results of such an approach have not been consistent [10–22]. The 
conflicting evidence arising from these studies utilising a cell-based approach has 
indirectly led to doubts of whether in vitro cellular responses are indeed an accurate 
indicator of in vivo tissue pathology given the potential modifying influence of the 
tissue environment [23, 24].
II.2 AIMS AND OUTLINE
This thesis describes a body of work performed in human skin tissues and blood 
lymphocytes of 35 individuals who displayed either moderate/marked (cases) or 
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minimal/no radiation-induced (controls) late changes in their breast following 
previous breast radiotherapy. Briefly, these patients were carefully selected from a 
group of previous participants of two breast radiotherapy trials, where radiation 
dosimetry and delivery of breast radiotherapy had withstood quality assurance, and 
patients were monitored annually for radiation-induced changes in the breasts [25, 
26]. For the first part, DSB repair was assessed using 53BP1 immunohistochemistry in 
human skin tissues which had been exposed to ionising radiation in vivo. As a unique 
aspect of this study, patients were subjected to a small test dose of 4 Gy delivered using 
electrons to a small area over their lower back skin. With strict dosimetric verification, 
a uniform radiation dose was delivered to the epidermis and dermis of the skin, thus 
ensuring that any biological variation observed between individuals or cells was not a 
result of variation in radiation dose delivery. Duplicate biopsies of irradiated and 
unirradiated skin were then obtained 24 hours following irradiation, and residual 
53BP1 foci levels were compared between different epidermal and dermal cell types in 
skin sections of these 35 patients. This analysis was primarily undertaken to determine 
if either cell-specific physiological factors or host-specific genetic or epigenetic factors 
play a greater role in modulating DSB repair in vivo.
Next, we proceeded to test if inter-individual variation in DSB repair could account 
for differences in clinical presentation of late normal tissue effects among breast 
radiotherapy patients. To this end, residual 53BP1 foci levels 24 hours after 4 Gy were 
assessed in in vivo irradiated skin tissues and ex vivo irradiated blood lymphocytes of 
the same patients, and mean residual 53BP1 foci levels of skin cells and lymphocytes 
were compared between cases and controls. The ability to measure in vivo cellular 
responses to ionising radiation in our skin model presents the opportunity to compare 
if cellular responses derived in vivo and ex vivo, given the contribution of tissue 
microenvironment in the former, produce similar levels of correlation with clinical 
phenotype. Separately, within this analysis, we also test the hypothesis that a cellular 
assay based on skin cells better predicts clinical responses in the human skin, as 
opposed to the same assay performed in blood lymphocytes.
Having then established lymphocytes as a valid cellular system for predicting normal 
tissue radiosensitivity, at least for late effects in skin, we performed further tests for 
biomarkers of clinical radiosensitivity using lymphocytes of a subset of eight severe 
cases from our original cohort of patients. Specifically, we examined if incremental 
responses of in vitro chromosomal radiosensitivity and radiation-induced apoptosis 
were indicative of overt and normal clinical responses to radiotherapy, respectively, as 
suggested by published literature [14–18]. In the attempt to draw the maximum 
difference in cellular responses between clinically radiosensitive individuals and 
controls, we consciously selected only the most clinically severe cases and controls 
with minimal reactions, particularly those who have had a lengthy follow-up, for this 
subgroup analysis. Based on these experimental findings, we also examined the 
relationships between chromosomal damage, induction of apoptosis, and residual 
DSB through crude correlation analyses. In particular, we designed specific experiments 
using small molecule inhibitors of ATM and DNA-PK to further characterise the 
mechanistic relationship between DSB repair and induction of apoptosis following 
radiation exposure. Finally, we identified a clinically radiosensitive individual among 
our cases who presented with extremely high levels of residual DSB and chromosomal 
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damage in her skin tissues and blood lymphocytes. In this individual, preliminary 
experiments were conducted to determine the nature of DSB repair defect and involved 
molecular pathway.
Following decades of unsuccessful research in the field of predicting normal tissue 
radiosensitivity using cell-based assays, this study was designed primarily with the aim 
of comparing a predictive assay based on an in vivo skin model against the historical 
approach of in vitro cell-based assays, in this case, blood lymphocytes. In addition to 
evaluating DSB repair as a potential biomarker of clinical radiosensitivity, we aimed to 
establish that in vivo cellular responses in skin predict for late adverse skin effects of 
radiotherapy and may well be the appropriate approach for predictive assays of normal 
tissue radiosensitivity going forward. Although limited by the small number of study 
participants, this was overcome by a meticulous selection process of cases and controls, 
taking into account several clinical parameters which could have contributed to their 
clinical phenotype. Judging from our study findings as detailed in the following 
chapters, we were able to derive a number of interesting hypotheses and conclusions 
regarding the biology of late normal tissue effects following radiotherapy.
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III.1 INTER-INDIVIDUAL AND INTER-CELL TYPE VARIATION 
IN RESIDUAL DNA DAMAGE AFTER IN VIVO  IRRADIATION OF 
HUMAN SKIN
III.1.1 Abstract
The aim of this study was to compare inter-individual and inter-cell type variation in 
DSB repair following in vivo irradiation of human skin. Duplicate 4 mm core biopsies 
of irradiated and unirradiated skin were collected from 35 patients 24 hours after 4 Gy 
exposure using 6 MeV electrons. Residual DSB were quantified by scoring 53BP1 foci 
in dermal fibroblasts, endothelial cells, superficial keratinocytes, and basal epidermal 
cells. Coefficients of inter-individual variation for levels of residual foci 24 hours after 
in vivo irradiation of skin were 39.9% in dermal fibroblasts, 44.3% in endothelial cells, 
32.9% in superficial keratinocytes, and 46.4% in basal epidermal cells (p < 0.001, 
ANOVA). In contrast, the coefficient of inter-cell type variation for residual foci levels 
was only 11.3% in human skin between the different epidermal and dermal cells 
(p = 0.034, ANOVA). Foci levels between the different skin cell types were correlated 
(Pearson’s R = 0.855-0.955, p < 0.001). Collectively, these findings suggest that patient-
specific factors appear to be more important than cell type-specific factors in 
modulating DSB repair following in vivo irradiation of human skin.
III.1.2 Introduction
Wide inter-individual variation in late-onset normal tissue damage has been reported 
after radiotherapy for early breast cancer delivered under very carefully controlled 
conditions, suggesting that factors intrinsic to the individual, including genetic 
determinants of cellular and tissue radiosensitivity, are responsible in explaining 
clinical responsiveness [1]. Apart from a limited number of rare genetic syndromes, the 
source of inter-individual variation in the majority of non-syndromic patients is 
unknown, but high frequency, low penetrance polymorphic alleles in a wide range 
of genes are potential candidates [2]. Whether sources of variation are genetic or 
epigenetic in origin, they might influence responses in all cells and tissues, as in A-T, or 
display some form of cell or tissue specificity, depending on the molecular pathway 
involved. After radiotherapy for early breast cancer, Bentzen et al. reported a lack of 
correlation between the frequency and severity of skin fibrosis and telangiectasia 
within patients [3]. A similar result was also reported by Tucker et al., who presented 
a lack of correlation between acute and late skin responses following post-mastectomy 
radiotherapy [4]. Collectively, these findings suggest relative differences in 
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radiosensitivity between different cell types, at least in the skin of an individual. These 
clinical findings are consistent with a lack of correlation between in vitro radiosensitivity 
of dermal fibroblasts, epidermal keratinocytes, and blood lymphocytes from the same 
patients [5–7]. In non-syndromic patients, the combined clinical and laboratory 
findings suggest sources of inter-patient variation in radiosensitivity that are cell type- 
or tissue-specific rather than generic to an individual.
The ability to repair DSB has been shown to correlate with cellular radiosensitivity 
in rare hyper-radiosensitivity syndromes and non-syndromic healthy controls [8–10]. 
It is however unclear if differences in intrinsic radiosensitivity between different cells 
of normal tissues are explained by differences in DSB repair kinetics. While several 
studies have reported cell-specific and differentiation-dependent DSB repair kinetics 
[11–14], a recent study of in vivo irradiated mouse tissues indicated similar initial DSB 
yields and repair kinetics for a range of different cells [15].
Early DSB repair signalling involves the phosphorylation of histone variant H2AX. 
Using immunofluorescence microscopy for the phosphorylated form of H2AX, 
discrete nuclear foci can be visualised at sites of DSB [16]. Foci of γ H2AX and 53BP1, 
which are recruited in large numbers to sites of DSB [17, 18], are now widely accepted 
surrogate markers for DSB induction and repair [19, 20]. In this study, we used 53BP1 
immunohistochemistry to compare residual DSB between different cell types in 
irradiated human skin from 35 breast cancer patients. The hypothesis under test was 
cell-specific physiological factors, in addition to intrinsic host factors, modulate repair 
of DSB in skin tissues of different individuals.
III.1.3 Materials and methods
III.1.3.1 In vivo irradiation of skin of breast cancer patients
Breast cancer patients were identified following local tumour excision and post-
operative radiotherapy to the whole breast for early invasive ductal carcinoma. 
Scientific and ethical approval were obtained from research ethics committees at all 
participating centres, and written informed consent was obtained from patients prior 
to participation. A single test dose of ionising radiation was delivered to a 4 × 2 cm2 
area of buttock skin at The Royal Marsden Hospital using a purpose-built endframe 
cutout. This incorporated a 7 mm Perspex filter to ensure dose homogeneity to the 
epidermis and dermis of the skin (Figure III.1). A single 4 Gy dose was delivered to 4 
mm depth below the skin surface at a dose rate of 4 Gy/minute with 6 MeV electrons 
using a linear accelerator. At 24 hours following irradiation, duplicate 4 mm punch 
biopsies were obtained from both irradiated and contralateral unirradiated skin. The 
biopsies were taken from the centre of the irradiation field to ensure dosimetric 
consistency. Tissues were then fixed in 10% neutral buffered formalin for 24 hours, 
embedded in paraffin, and sectioned at an average thickness of 5 μm.
III.1.3.2 53BP1 immunohistochemistry in skin sections
To ensure accurate morphological identification of the different cell types and avoid 
dermal collagen auto-fluorescence with immunofluorescence techniques, chromogenic 
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staining method was chosen for 53BP1 immunohistochemistry. 53BP1 was preferred to 
γ H2AX as a marker for DSB as foci obtained using 53BP1 immunostaining were more 
consistent in staining quality and easier to score in skin sections. Tissue sections were 
heated to 60˚C for 10 minutes, followed by de-waxing, and rehydration in a graded 
series of alcohol. Following microwave treatment in 10 mM citric acid (pH titrated to 
6.0), DAKO peroxidase and protein blocks (DAKO, Cambridgeshire, UK) were applied 
onto sections for 5 and 2 minutes, respectively. Tissue sections were then incubated for 
90 minutes with 53BP1 rabbit polyclonal antibody (IHC-00001, Bethyl Laboratories, 
Universal Biologicals, Cambridge, UK) diluted to 1:400. The primary antibody was 
detected using DAKO Envision kit after a further three washes with Tris-buffered 
saline. The slides were then lightly counter-stained with Gill’s No. 1 haematoxylin and 
mounted in DPX for analysis under light microscopy at 600× magnification. 53BP1 
nuclear foci were visually counted in dermal fibroblasts, endothelial cells, and 
epidermal cells, with 50 to 100 cells scored for each cell type per biopsy. Heat shock 
protein 47 (Hsp47, Stressgen, York, UK, 1:200) and CD31 (CD31-1A10, Novocastra, 
Newcastle Upon Tyne, UK, 1:150) immunostaining were used in the initial stages on 
serial sections to practise and confirm the histomorphological identification of dermal 
fibroblasts and endothelial cells, respectively (Figures III.2A, D). Basal and suprabasal 
epidermis were considered separately using the following criteria, 1) superficial 
keratinocytes (suprabasal epidermis) defined as cells residing in the junction of stratum 
granulosum and spinosum, 2) basal epidermal cells were keratinocytes in the stratum 
basale (Figures III.2G, H).
III.1.3.3 Statistical methods
Inter-cell type and inter-individual variation in foci levels were tested using one-way 
analysis of variance (ANOVA) and Bonferroni post-hoc tests. Inter-biopsy variation 
was tested using the Paired T-test. Pearson’s correlation method was used to test for 
correlation in foci levels between the different cells. All statistical calculations were 
performed using the statistical software SPSS version 15.0 (SPSS, Inc., Chicago, IL). To 
Figure III.1 Depth dose of 6 MeV electrons for 4 cm × 2 cm endframe cutout. Dose (Gy) 
plotted against depth (mm) below surface of a 7 mm Perspex filter on skin surface, confirming 
uniform dose profile across dermis.
38 Original research
account for multiple statistical testing, statistical significance was set at a p-value of 
< 0.01.
III.1.4 Results
III.1.4.1 Patients
35 breast cancer patients were enrolled into the study. Ages of all patients ranged from 
52 to 83 years, with the median age being 68.5 years.
III.1.4.2 Quantification of 53BP1 foci in different skin cell types
Examples of 53BP1 immunostaining in skin sections are illustrated in Figure III.2. 
Using 53BP1 immunohistochemistry, multiple 53BP1 foci could be visualized in the 
nuclei of dermal fibroblasts (C), endothelial cells (F), superficial keratinocytes, and 
basal epidermal cells (H) in the irradiated skin sections. Few, if any, foci were seen in 
unirradiated dermal fibroblasts (B), endothelial cells (E), and superficial keratinocytes, 
other than in basal epidermal cells (G) where foci were more frequent. Mean 
background foci levels per cell in unirradiated skin were 0.48 in dermal fibroblasts, 0.37 
in endothelial cells, 0.27 in superficial keratinocytes, and 2.18 in basal epidermal cells.
Figure III.2 Immunohistochemical staining of 5 μm-thick skin sections from formalin-
fixed, paraffin-embedded skin biopsies obtained 24 hours after treatment with 4 Gy. Hsp47 
staining in dermal fibroblasts (A) and CD31 staining in endothelial cells (D). 53BP1 staining 
in unirradiated and irradiated dermal fibroblasts (B, C), endothelial cells (E, F), superficial 
keratinocytes, and basal epidermal cells (G, H). Grey arrows indicate superficial keratinocytes 
and black arrows indicate basal epidermal cells.
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III.1.4.3 Correlation of 53BP1 foci quantification in duplicate skin biopsies
To test for possible sources of variation in radiation dosimetry, tissue collection, 
fixation, block preparation, tissue sectioning, immunostaining, and/or foci scoring, 
quantification of 53BP1 foci for the different cell types was repeated in duplicate skin 
biopsies from the same patients. Figure III.3 shows similar levels of 53BP1 foci in both 
biopsies (p = 0.378, Paired t-test; Pearson’s correlation R = 0.944, p < 0.001). The high 
correlation validates the above procedures, which were performed independently on 
duplicate core biopsies. 
III.1.4.4 Inter-individual variation in residual foci levels
Table III.1 lists patient-specific levels of uncorrected 53BP1 foci scored for all the 
different cell types at 24 hours after 4 Gy irradiation. These levels varied significantly 
between patients, with coefficients of inter-individual variation of 39.9% for dermal 
fibroblasts, 44.3% for endothelial cells, 46.4% for basal epidermal cells, and 32.9% for 
superficial keratinocytes after normalizing against background foci levels in 
unirradiated skin (p < 0.001, one-way ANOVA for all cell types).
Patients in Table III.1 were ordered according to ascending levels of foci measured in 
dermal fibroblasts. Average foci levels were divided into quartiles for each cell type and 
colour codes applied as follow; white for the 25% of patients with lowest number of 
foci, and increasing shades of grey for higher quartiles. Mostly, colour codes tend to 
correspond for dermal fibroblasts, endothelial cells, and epidermal cells.
In view of the patient-specific clustering of quartiles of foci levels across different 
skin cell types at 24 hours (Table III.1), a test of association of foci levels between the 
Figure III.3 Correlation of 53BP1 foci levels in duplicate biopsies obtained 24 hours after 
4 Gy exposure. Each circle represents average foci per cell for a single cell type in a single 
patient. Trendline was generated using linear regression and intercepted the y-axis at 0.23 with 
a corresponding R2 value of 0.891.
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different cell types within the same patients was performed (Table III.2). Positive 
correlation for foci levels was observed between all the skin cell types from the same 
patients
Table iii 1 53BP1 foci levels in skin measured 24 hours after 4 Gy delivered using 6 
MeV electrons with full build-up. At least fifty cells were scored for each cell type per 
patient and repeated in duplicate biopsies. Indicated foci levels represent averages of 
duplicate biopsies, and are colour-coded in quartiles of increasing shades of grey.
Patients
Cell types
Dermal 
fibroblasts
Endothelial 
cells
Basal epidermal 
cells
Superficial 
keratinocytes
1 0.79 0.77 0.96 0.65
2 2.01 2.60 3.92 2.21
3 2.15 1.43 4.48 1.95
4 2.26 1.88 3.25 2.09
5 2.36 2.13 3.56 2.44
6 2.45 2.50 4.07 2.30
7 2.57 2.29 4.03 2.15
8 2.57 2.03 2.77 1.34
9 2.66 2.94 3.78 2.07
10 2.76 2.87 5.11 2.98
11 2.88 2.62 3.90 2.03
12 2.93 2.88 3.82 2.84
13 2.94 3.11 4.18 2.52
14 3.01 3.32 4.15 2.87
15 3.02 2.77 4.31 2.76
16 3.03 2.60 3.59 1.77
17 3.10 3.30 4.44 1.55
18 3.11 3.16 3.43 2.69
19 3.26 4.21 5.40 2.52
20 3.32 2.00 4.85 2.86
21 3.41 3.16 5.43 3.43
22 3.42 3.64 4.78 2.84
23 3.43 1.94 4.24 2.09
24 3.44 2.88 4.96 1.50
25 3.52 2.95 5.56 3.00
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Patients
Cell types
Dermal 
fibroblasts
Endothelial 
cells
Basal epidermal 
cells
Superficial 
keratinocytes
26 3.53 3.68 5.01 2.93
27 3.66 3.68 4.90 2.50
28 3.69 3.47 4.93 3.37
29 3.78 3.37 4.94 2.96
30 4.05 4.42 5.44 4.32
31 4.34 4.65 6.70 3.02
32 4.50 4.43 4.64 3.34
33 5.90 4.10 5.18 4.08
34 9.93 9.52 9.16 5.79
35 10.30 9.83 8.92 5.74
Table III.2 Correlation of patient-specific foci levels between the different skin cell 
types at 24 hours after a single dose of 4 Gy to human skin using 6 MeV electrons.
Cell types
Dermal 
fibroblasts
Endothelial 
cells
Basal 
epidermal 
cells
Superficial 
keratinocytes
Dermal 
fibroblasts
Pearson 
correlation
0.955 0.885 0.875
p-value
(2-tailed)
< 0.001 < 0.001 < 0.001
N 35 35 35
Endothelial 
cells
Pearson 
correlation
0.897 0.870
p-value
(2-tailed)
< 0.001 < 0.001
N 35 35
Basal 
epidermal 
cells
Pearson 
correlation
0.855
p-value
(2-tailed)
< 0.001
N 35
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III.1.4.5 Inter-cell type variation in residual foci levels
Comparable levels of patient-average residual foci 24 hours after 4 Gy irradiation were 
observed in four epidermal and dermal cell types. After normalizing against 
background foci levels, mean foci per cell were 3.14 in dermal fibroblasts, 3.06 in 
endothelial cells, 2.51 in superficial keratinocytes, and 2.63 in basal epidermal cells 
(p = 0.034, one-way ANOVA, Figure III.4).
III.1.5 Discussion
Significant variation between women in the level of residual 53BP1 foci 24 hours after 
a single in vivo dose of 4 Gy to healthy skin was observed in this study of 35 former 
breast cancer patients. The coefficients of inter-individual variation for the different 
skin cell types ranged from 32.9% to 46.4% in this cohort of patients and are generally 
comparable with previous studies [10, 21]. In contrast, coefficient of inter-cell 
type variation was only 11.3% between epidermis, dermal fibroblasts, and dermal 
endothelium.
Levels of induced DSB per unit of radiation dose in different individuals appear to 
be similar, as judged by the absence of detectable inter-individual variation in induced 
DSB yields following irradiation in patients with rare hyper-radiosensitivity syndromes, 
non-syndromic cancer patients, and healthy controls [22]. In a separate study involving 
the same patients, we observed only limited inter-individual variation in foci levels of 
ex vivo irradiated blood lymphocytes 30 minutes after exposure to 0.5 Gy X-rays, 
which would be consistent with this notion [23]. We conclude that the significant inter-
individual variation in residual (24 hours) foci levels in skin cells is therefore indicative 
of significant differences in DSB repair kinetics between individuals.
Figure III.4 Patient-averaged 53BP1 foci levels in different cell types. Foci levels were 
normalized against background levels from the same patients to derive levels of residual 
damage. Error bars indicate one standard deviation of foci levels for the whole cohort.
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It may be argued that outliers (patients 34 and 35, Table III.1) who had extremely 
high levels of residual foci in the different skin cells compared to other members of the 
study cohort might have provided a major contribution to inter-individual variation in 
residual foci. With the exclusion of these outliers, coefficients of inter-individual 
variation remained significant for the different skin cell types, 33.0% in dermal 
fibroblasts, 33.9% in endothelial cells, 33.6% in superficial keratinocytes, and 34.9% 
in basal epidermal cells.
In this study, we demonstrated the reliability of 53BP1 immunohistochemistry using 
chromogenic techniques for scoring of residual DSB in skin tissues which had 
been exposed to a test dose of ionising radiation in vivo. Although foci analysis with 
immunofluorescence staining would invariably be more sensitive compared to 
chromogenic staining, the presence of significant collagen auto-fluorescence in the 
dermis limited the use of this technique in the study (Figure III.5). Using chromogenic 
immunohistochemistry, we observed few, if any, 53BP1 foci in unirradiated skin cells, 
with the exception of cells residing in the basal epidermis. The higher than expected 
background foci levels in basal epidermal cells were probably attributed to endogenous 
generation of DSB during DNA replication in these proliferating cells [24, 25]. After 
normalising against background levels, comparable residual foci levels were observed 
between the different epidermal and dermal cells, which are consistent with similar 
DSB repair kinetics in different cell types within the skin of an individual, as reported 
in the mouse [15, 26].
Figure III.5 γ H2AX/53BP1 immunofluorescence staining of unirradiated and irradiated 
(4 Gy) skin sections. Although co-localising γ H2AX/53BP1 foci (yellow) were readily observed 
in irradiated dermal fibroblasts 24 hours post-irradiation, significant auto-fluorescence (red) 
in the adjacent collagen fibres often interfered with foci scoring in these cells. Scale (top left 
panel) = 10 μm.
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An apparent lack of correlation between the severity of skin fibrosis and telangiectasia 
despite good control of radiotherapy doses in patients with early breast cancer suggests 
that, in non-syndromic patients, inter-individual differences in clinical radiosensitivity 
are perhaps cell type- and tissue-specific [3]. Our findings, together with that of Rübe 
et al. [15, 26], suggest that DSB repair may not be the predominant factor contributing 
to these cell type- and tissue-specific differences. In the case of radiation fibrosis, 
although DDR is important in the activation of myofibroblasts, there are other possible 
pathways leading to fibrogenesis which are independent of DDR [27]. For example, 
latent TGFβ1 sequestered in extracellular matrix is hydrolytically cleaved by reactive 
oxygen species with the release of active cytokines [28]. In this model of radiation-
induced fibrosis, no correlation with other end-points relating to post-radiation late 
skin effects would be expected.
III.1.6 Conclusions
In conclusion, the findings from this study suggest that inter-individual variation in 
DSB repair is more pronounced than inter-cell type variation, at least in skin. It is 
possible that in phenotypically normal patients, genetic and epigenetic factors specific 
to the individual play a more important role than cell type-specific factors in modulating 
DSB repair in vivo. If so, a lack of association between telangiectasia and fibrosis in the 
same patient despite good control of dose would suggest different cell type-specific 
responses to similar levels of residual DNA damage that are independent of DSB repair.
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III.2 DSB REPAIR FOLLOWING IN VIVO  AND EX VIVO 
IRRADIATION OF SKIN TISSUES AND BLOOD LYMPHOCYTES IN 
RELATION TO LATE EFFECTS OF BREAST RADIOTHERAPY
III.2.1 Abstract
To test if residual DSB in skin tissues and G0 blood lymphocytes 24 hours following 4 
Gy in vivo and ex vivo exposure, respectively, correlated with late radiation-induced 
skin effects of breast radiotherapy patients. In the preceding study, residual DSB were 
quantified using 53BP1 immunostaining in irradiated skin tissues of 35 breast 
radiotherapy patients. These patients were selected on the basis of late radiation-
induced changes in their breast and individuals with moderate/marked or minimal/no 
change were classified as cases and controls, respectively. Among them, 30 patients 
agreed to peripheral blood sampling. G0 blood lymphocytes of these patients were 
irradiated with 4 Gy X-rays ex vivo, and residual DSB were quantified by γ H2AX/53BP1 
immunofluorescence microscopy 24 hours later. Residual foci levels in dermal and 
epidermal cell types were not significantly different between cases (n = 20) and controls 
(n = 15). Mean foci per cell were 3.29 in cases and 2.80 in controls for dermal fibroblasts 
(p = 0.07), 3.28 in cases and 2.60 in controls for endothelial cells (p = 0.08), 2.87 in cases 
and 2.41 in controls for superficial keratinocytes (p = 0.45), and 2.32 in cases and 2.35 
in controls for basal epidermal cells (p = 0.27). Mean residual foci levels in blood 
lymphocytes were however significantly higher among cases (n = 17, foci per cell = 
12.1) compared to controls (n = 13, foci per cell = 10.3, p = 0.01). Of the different cell 
types, only residual foci levels of in vivo irradiated dermal fibroblasts and ex vivo 
irradiated blood lymphocytes correlated with severity of late effects among cases 
(Spearman R = 0.722, p < 0.001; 0.593, p = 0.01, respectively). These findings suggest 
that DSB repair ex vivo in G0 blood lymphocytes may be predictive of late normal 
tissue responses after breast radiotherapy.
III.2.2 Introduction
Processes relevant to cellular radiosensitivity include the recognition and repair of 
DSB, as evident by the increased cellular and clinical radiosensitivity observed in 
individuals harbouring a defective DSB repair phenotype [1]. Nonetheless, contrary to 
the early successes of small case-control studies indicating a correlation between in 
vitro cellular radiosensitivity and clinical responses following radiation exposure, 
subsequent studies seeking to establish DSB repair as a predictive marker of normal 
tissue radiosensitivity have largely been inconclusive [2–6]. Critical opinions for the 
lack of success with this assay include the argument that in vitro cellular responses 
correlate poorly with in vivo responses due to the modifying influence of tissue 
environment [7, 8]. Hence, there is a powerful argument to exploring ways of measuring 
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cellular responses to radiotherapy ex vivo. Separately, the choice of an ideal cellular 
system for a predictive assay is also a contentious issue. For example, the lack of 
correlation between late fibrosis and telangiectasia in breast radiotherapy patients 
suggests that predictive assays should be aimed at a specific normal tissue end-point 
[9]. In the case of late fibrosis and telangiectasia, this would imply measuring cellular 
responses in dermal fibroblasts and endothelium of the skin, respectively. Nonetheless, 
opposing evidence to this model can be derived from studies demonstrating a modest 
correlation between in vitro cellular responses in lymphocytes and in vivo late tissue 
effects [10–12].
In the previous study, 53BP1 foci analyses were performed ex vivo in test-irradiated 
buttock skin of 35 breast cancer patients. These patients were selected on the basis of 
late adverse effects to previous breast radiotherapy, comprising of individuals with 
moderate/marked (cases) or little/no radiation-induced change (controls) in their 
breast. In an attempt to select cases and controls whose phenotype most likely 
represents their intrinsic radiosensitivity, we employed a manner of patient stratification 
where clinical parameters of normal tissue response following breast radiotherapy 
were considered. Here, we examined if DSB repair measured in skin following in vivo 
irradiation discriminates between non-syndromic individuals varying in severity of 
radiation-induced late skin effects. Additionally, DSB repair was assessed in ex vivo 
irradiated G0 blood lymphocytes of the same individuals to determine if lymphocytes 
are a valid alternative cellular system for predicting normal tissue responses following 
radiation exposure.
III.2.3 Materials and methods
III.2.3.1 Selection of cases and controls
The volunteers in our study comprised of patients who were previously diagnosed 
with early invasive ductal carcinoma of the breast and had enrolled into two breast 
radiotherapy randomised trials, involving treatment under standard conditions and 
prospective annual clinical assessments of late adverse effects using standard proformas 
[13, 14]. In addition to conventional scoring methods (common terminology criteria 
for adverse events (CTCAE) version 3.0), late adverse effects in the breasts were further 
evaluated by comparing pre- and post-radiotherapy photographs of both breasts, 
collected under predefined conditions before radiotherapy and at 1, 2, and 5 years post-
radiotherapy. Specifically, the late effects graded with comparisons of pre- and post-
radiotherapy photographs include 1) breast asymmetry, 2) telangiectasia, 3) hyper- or 
hypo-pigmentation, 4) increased breast density, 5) oedema, 6) subcutaneous fibrosis, 
and 7) aesthetic sequelae. Patients were then selected in the following manner. Initial 
selection was based on clinical and photographic assessments indicating moderate/
marked radiation-induced change (case) or very little/no change (control) (Figure 
III.6). Following which, clinical parameters associated with an elevated risk of 
radiation-induced change in breast appearance were assessed in these patients to derive 
the most informative individuals. These factors were generated by multivariate 
analyses of outcomes in the breast radiotherapy trials and namely, they were 1) 
prescribed whole breast radiotherapy dose, 2) radiation dosimetry, 3) radiotherapy 
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boost to tumour bed, 4) breast size, 5) proportion of breast removed at surgery, and 6) 
axillary treatment (Table III.3). Taking into account these clinical parameters, an 
unmatched case-control study design was attempted, such that selected cases, in spite 
of favourable treatment conditions which would have gone against the risk of 
developing late adverse effects in the breasts, presented with moderate/marked 
changes, whereas controls had minimal/no change despite their predicted risk of 
increased late events following unfavourable treatment conditions. As an added 
consideration, the cases selected would have shown changes in their breast at early 
time points after radiotherapy, while controls would exhibit little/no symptoms out to 
a minimum of 5 years post-radiotherapy. After the selection of two potential groups 
according to the above criteria, the final selection was made by two experienced 
clinicians (JY and NS1) with primary reference to the photographic scoring of pre- and 
1 JY, John Yarnold; NS, Navita Somaiah
Figure III.6 Illustrative examples of a control and case in the study as determined by 
comparisons of post-surgical photographs taken pre- (top panels) and post-radiotherapy 
(bottom panels). The irradiated breasts are indicated by the grey arrows. To demonstrate the 
degree of radiation-induced change, an arbitrary red line is drawn across the infra-mammary 
fold of the irradiated breast. In contrast to the control where there is minimal change observed 
following radiotherapy despite the presence of appreciable loss of breast volume following 
surgery, marked retraction with hardening of the irradiated breast is evident in the selected 
case. Patients had kindly consented to the use of these photographs for illustrative purposes. 
Abbreviation = RT, radiotherapy.
DSB repair and late radiotherapy toxicities 49
post-radiotherapy changes, excluding individual patients for whom factors omitted by 
the algorithm were considered to influence response. An illustrative example would be 
tumour location in the inferior quadrants of the breast where breast contour is very 
irregular and accurate radiotherapy dosimetry was difficult to ensure. Ethical approval 
was obtained from research ethics committees at all participating centres. Informed 
consent was obtained from patients prior to participation.
III.2.3.2 Skin irradiation, 53BP1 immunohistochemistry, and foci analyses of skin 
sections
A test dose of 4 Gy was delivered to a small area of buttock skin using 6 MeV electrons. 
Duplicate biopsies of irradiated and unirradiated skin were obtained and processed 
for 53BP1 immunohistochemistry. 53BP1 foci were scored in four epidermal and 
dermal cell types, namely superficial keratinocytes, basal epidermal cells, dermal 
fibroblasts, and endothelial cells, with 50 to 100 cells scored for each cell type per 
biopsy of each patient. Details entailing irradiation, 53BP1 immunostaining, and foci 
analyses of skin were described earlier in Chapter III.1.3.
Table III.3 Determinants of late adverse effects following breast radiotherapy 
established by multivariate analyses of outcomes of two breast radiotherapy trials  
(n = 1716) [13, 14]. Odds ratios are presented relative to favourable factors, which are 
lower radiotherapy dose, 3D dosimetry, no boost dose, small breast size, minimal 
surgical cavity, and no axillary treatment.
Clinical parameters Odds ratio for late RT-induced effects  
(95% confidence interval)
RT dose (39, 41, 50 Gy) 1.09 (1.01–1.17), p = 0.02
Radiation dosimetry
(3D dosimetry versus standard 2D wedge)
1.71 (1.15–2.54), p = 0.008
Boost dose to tumour bed
(none, 11.1, 15,5 Gy)
1.03 (1.02–1.05), p < 0.001
Breast size
(small, medium, large, odds for per increase 
in cup size)
1.19 (1.12–1.26), p < 0.001
Surgical deficit (small, medium, large) Medium = 2.00 (1.23–3.25), 
Large = 1.38 (0.57–3.37), p = 0.009
Axillary treatment (none, surgery, RT) Surgery = 1.38 (0.72–2.63),
RT = 2.49 (1.20–5.18), p = 0.05
Abbreviation = RT, radiotherapy.
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III.2.3.3 Peripheral blood separation and G0 blood lymphocyte irradiation
Thirty patients from the same cohort also consented to repeated peripheral blood 
sampling. G0 blood lymphocytes were isolated from whole blood samples using 
Histopaque-1077 (Sigma-Aldrich, Dorset, UK). Whole blood samples, delivered 
overnight from the Royal Marsden Hospital, Sutton, to the Health Protection Agency, 
Chilton, were diluted in equal volumes (1:1) of Hank’s buffered solution (Invitrogen, 
Paisley, UK) before layering onto Histopaque-1077. Samples were then spun at 350 × g 
for 40 minutes, 21°C, and upon completion, the opaque interface (containing the 
blood lymphocytes) between the upper plasma layer and Histopaque-1077 was 
carefully aspirated. After washings with Hank’s buffered solution, blood lymphocytes 
were exposed to 0.5 and 4 Gy using 250 kV X-rays delivered at 0.69 Gy/min (Pantak, 
Surrey, UK). They were then incubated in minimum essential medium (Invitrogen, 
Paisley, UK), supplemented with 1% L-glutamine, 1% streptomycin, 10% fetal calf 
serum, and kept for 0.5 (0.5 Gy) and 24 hours (4 Gy) in a 37°C, 5% CO2 incubator prior 
to immunostaining.
III.2.3.4 DSB in ex vivo irradiated G0 blood lymphocytes
DSB in irradiated blood lymphocytes were quantified using γH2AX and 53BP1 
immunostaining and co-localizing γ H2AX and 53BP1 foci were scored (Figure III.7). 
For immunostaining, cells were plated on glass slides, fixed and permeabilised for 10 
minutes with 2% paraformaldehyde and 0.5% Triton X-100 in PBS, respectively, washed 
with PBS, and blocked for 30 minutes with PBS + 1% BSA fraction V (Sigma-Aldrich, 
Dorset, UK). Cells were then incubated with primary antibody diluted in PBS + 1% 
Figure III.7 γ H2AX and 53BP1 immunofluorescence staining 24 hours after 4 Gy X-irradiation 
in G0 blood lymphocytes. Blood lymphocytes were co-stained with DAPI (top left panel), anti- 
γ H2AX antibody (green), and anti-53BP1 antibody (red). γ H2AX and 53BP1 foci co-localise 
in the cell nuclei as evident by the yellow-coloured foci (bottom right panel), product of the 
merging of green and red colours. Scales = 10 μm.
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BSA fraction V for 1 hour at room temperature, washed twice, and incubated with 
secondary antibody and DAPI (4´,6-diamidino-2-phenylindole) diluted in PBS + 1% 
BSA fraction V for 1 hour at room temperature in the dark. After final washes with PBS 
and drying, slides were mounted in Vectashield (Vector Laboratories Limited, 
Peterborough, UK) and visualized using a Nikon Eclipse TE200 epifluorescence 
microscope (Nikon UK Limited, Surrey, UK). At least 50 cells were scored per slide for 
each patient. The following antibodies were used: anti-53BP1 (mab3802, Millipore, 
Watford, UK, 1:400 and ab36823, Abcam, Cambridge, UK, 1:400) and anti-γ H2AX 
(05-636, Millipore, 1:500, ab18311 and ab26350, Abcam, 1:500) primary antibodies, 
Alexa-Fluor 488 goat anti-mouse, Alexa-Fluor 555 goat anti-rabbit (Invitrogen, Paisley, 
UK, 1:200), and TRITC (Tetramethylrhodamine-5-(and-6)-isothiocyanate, Jackson 
immunoresearch, Suffolk, UK, 1:200) donkey anti-rabbit secondary antibodies.
III.2.3.5 Statistical methods
To avoid biases in foci scoring, the following blinding process was employed. Skin 
tissue blocks and peripheral blood samples of each patient were randomly recoded by 
an independent third party prior to transfer from The Royal Marsden Hospital. As an 
added measure of blinding, skin tissue blocks and peripheral blood samples of each 
corresponding patient were also assigned different codes such that it would not be 
known to the scorer if the skin and blood samples came from the same source. The 
manner of coding, along with the patients’ clinical phenotype (case/control) were 
revealed for data analysis only upon the completion of foci scoring.
The study was originally designed to recruit 15 cases and 15 controls to detect a 
standardised difference of 1.2 with 85% power (5% two-sided significance level). 
Comparative analyses of clinical parameters and foci levels between cases and controls 
were performed using the Mann-Whitney U test. Spearman’s rank correlation test was 
used to test for correlation of residual foci levels in the different cell types and clinical 
severity of late effects among cases. However, as these tests of association were 
secondary analyses undertaken on an exploratory basis, conservative p-values (p < 0.01) 
were employed in their interpretation. Statistical calculations were performed using 
SPSS version 15.0.
III.2.4 Results
III.2.4.1 Cases and controls
Of 35 breast radiotherapy patients who volunteered for the study, 20 and 15 patients 
were recruited as cases and controls, respectively. Among them, 17 cases and 13 controls 
consented to repeated peripheral blood sampling. Median age of cases and controls 
was 70 and 68 years, respectively. Patients’ characteristics, including treatment-related 
parameters, are summarised below in Table III.4. It is evident from the table that 
treatment characteristics of the selected cases and controls did not match the original 
intent of stratifying these patient cohorts based on favourable and unfavourable 
clinical determinants of late effects following breast radiotherapy, respectively (Table 
III.3). Nonetheless, it is still noteworthy that these factors were comparable between 
both groups of patients.
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Table III.4 Parameters of cases and controls*
Cases Controls
Patients (n = 35) 20 15 
Median age, years (range) 70 (52–83) 68 (54–78)
Median follow-up, years (range) 11 (3–24) 13 (11–24)
Mean breast RT dose, Gy (±SD) 47.2 (±6.26) 48.6 (±2.94)
Dosimetry techniques
3D
2D
10
10
3 
12 
Mean tumour bed boost dose, Gy (±SD) 9.78 (±6.11) 12.66 (±2.03)
Breast size
Small
Medium
Large
8
10
2
2 
13 
Surgical deficit
Small
Medium
Large
8
8
4 (1 Mastectomy)
11
3
1
Axillary treatment 15 11
Tamoxifen 14 12
Chemotherapy 8 5
* There were no significance differences between groups. All cases and controls received breast 
radiotherapy for treatment of early invasive ductal carcinoma of the breast. SD = One 
standard deviation.
III.2.4.2 Residual foci levels of in vivo irradiated skin in cases and controls
Patient-averaged levels of residual foci 24 hours after 4 Gy in epidermal and dermal 
skin cells were not significantly different between cases and controls (Figure III.8). 
Mean foci per cell were 3.29 in cases and 2.80 in controls for dermal fibroblasts 
(p = 0.07), 3.28 in cases and 2.60 in controls for endothelial cells (p = 0.08), 2.87 in cases 
and 2.41 in controls for superficial keratinocytes (p = 0.45), and 2.32 in cases and 2.35 
in controls for basal epidermal cells (p = 0.27).
Figure III.9 illustrates the individual foci levels in dermal fibroblasts, endothelial 
cells, superficial keratinocytes, and basal epidermal cells for all cases and controls 
within the cohort. Although patient-averaged residual foci levels in these skin cells 
were not significantly different between both patient groups, in a few selected cases, 
foci levels present in the dermis and superficial keratinocytes 24 hours after 4 Gy were 
significantly higher compared to the majority of controls.
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Figure III.8 Patient-averaged residual foci levels in the different skin cells 24 hours after 4 Gy. 
Error bars represent one standard deviation.
Figure III.9 Individual foci levels scored in irradiated skin of cases and controls 24 hours after 
4 Gy. Horizontal lines represent patient-averaged residual foci levels.
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To ascertain the significance of these increased residual foci levels in a subset of 
cases, we proceeded to test if residual foci levels of in vivo irradiated skin correlated 
with severity of late radiation-induced skin changes in our cohort of 20 cases. As 
mentioned earlier, late radiation-induced changes in the breasts were scored based on 
a combination of clinical and serial photographic assessments pre- and post-
radiotherapy (Chapter III.2.3.1). For the purpose of this exploratory analysis, clinical 
symptoms of cases were further graded using an arbitrary scale of one to three, in 
ascending order of severity. This clinical classification of cases was performed with 
primary reference to photographic assessments of late adverse effects in the breasts, 
taking into account parameters such as 1) breast asymmetry, 2) telangiectasia, 3) 
hyper- or hypo-pigmentation, 4) increased breast density, 5) oedema, 6) subcutaneous 
fibrosis, and 7) aesthetic sequelae. On the basis of clinical impression of the severity of 
the aforementioned, two experienced oncologists (JY and NS1), while blinded to the 
foci scores and patients’ identification on the pre- and post-radiotherapy photographs, 
then independently assigned ten, four, and six cases to groups one, two, and three, 
respectively. Illustrative examples of cases classified under the respective groups are 
presented in Figure III.10.
Of the different skin cells, only residual foci levels in dermal fibroblasts were 
correlated with clinical symptoms of the same cases (Spearman’s R = 0.722, p < 0.001). 
Although a positive association was observed between residual foci levels in endothelial 
cells and clinical severity for the same cases, this was not statistically significant 
(Spearman’s R = 0.506, p = 0.023). No association was observed between residual foci 
levels in the epidermis and clinical severity of cases (superficial keratinocytes, 
Spearman’s R = 0.062, p = 0.794; basal epidermal cells, Spearman’s R = 0.121, 
Figure III.10 Post-surgical photographs of cases with varying degree of late effects in the 
irradiated breast (grey arrow) at 5 years post-radiotherapy. Compared to the cases assigned 
to group one (least severe), cases categorised into groups two (moderately severe) and three 
(most severe) displayed enhanced toxicities from breast radiotherapy, including marked breast 
hardening, significant loss of breast volume, and overlying skin telangiectasia. Consent was 
obtained from patients for the use of these photographs.
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p = 0.611). Figure III.11 illustrates the levels of association between residual foci levels 
in the different skin cells and clinical severity for the same cases.
III.2.4.3 Foci levels of ex vivo irradiated G0 blood lymphocytes in cases and controls
In contrast to residual foci levels of in vivo irradiated skin, foci levels of G0 blood 
lymphocytes 24 hours after 4 Gy X-rays ex vivo were significantly higher in cases 
compared to controls. Mean foci per cell were 12.1 in cases versus 10.3 in controls 
(Figure III.12, p = 0.01). Foci levels in G0 blood lymphocytes 0.5 hour after 0.5 Gy 
Figure III.11 Individual residual foci levels in the different skin cells for all cases, grouped 
according to their severity of late skin effects, where one represents the least severe and three, 
the most severe. Horizontal lines represent patient-averaged foci levels for all cases classified 
under the same ‘grade’ of clinical severity. R2 values were generated using Spearman’s rank 
correlation test with corresponding p-values indicated in brackets.
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X-rays ex vivo were however comparable between both groups of patients (mean foci 
per cell = 7.70, cases versus 8.05, controls, p = 0.16, Figure III.12).
Given the difference in residual foci levels of ex vivo irradiated G0 blood lymphocytes 
between cases and controls, we proceeded to test if foci levels of this cell type correlated 
with severity of late radiation-induced skin changes for the same cases. Like dermal 
fibroblasts, a positive patient-specific association was observed between residual foci 
levels 24 hours after 4 Gy X-irradiation in blood lymphocytes and severity of clinical 
symptoms among cases (Figure III.13, Spearman’s R = 0.593, p = 0.01).
III.2.5 Discussion
Ex vivo measurements of residual DSB levels in test-irradiated buttock skin of breast 
radiotherapy patients failed to discriminate between individuals with varying severity 
of late radiation-induced skin effects. On the contrary, DSB repair assessed in G0 blood 
lymphocytes of the same patients indicated higher levels of residual γ H2AX/53BP1 
foci among clinically radiosensitive individuals compared to matched controls. 
Exploratory secondary analyses suggest a positive association between residual foci 
levels and severity of late effects among cases (patients with moderate/marked late 
radiation-induced change in their breast), albeit only in dermal fibroblasts and blood 
lymphocytes. Together, these findings propose that cellular responses in blood 
lymphocytes are potentially indicative of normal tissue radiosensitivity in non-
syndromic individuals.
The basis of testing residual DSB as a marker of clinical radiosensitivity in this study 
was extrapolated from consistent reports of a slow component to tissue recovery 
between fractions during radiotherapy [15–17]. For example, in breast radiotherapy 
patients treated using once daily or twice daily (8 hours interval) fractions to the 
breasts, increased incidence and severity of late telangiectasia in skin irradiated twice 
daily were equivalent to a 10% increase in total dose [16]. Likewise, long repair 
Figure III.12 Individual foci levels in ex vivo irradiated blood lymphocytes of 17 cases and 
13 controls of the original cohort of 35 patients. Horizontal lines represent patient-averaged 
foci levels.
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halftimes have been estimated for a number of late normal tissue end-points, such as 
skin telangiectasia and fibrosis, based on clinical outcomes of altered fractionated 
radiotherapy regimes in head and neck cancers [17]. Judging from these findings, it is 
plausible to hypothesise that residual DSB levels prior to the next fraction of 
radiotherapy have a profound influence on cell fate, including cell cycle arrest, 
senescence, apoptosis, and inter-individual variation in DSB repair could therefore 
account for variation of late normal tissue responses between radiotherapy patients.
As reported in the preceding chapter, residual 53BP1 foci levels in different epidermal 
and dermal cells 24 hours after 4 Gy in vivo irradiation varied significantly among 
patients from our study cohort. Nonetheless, a comparison of residual foci levels in 
these irradiated skin tissues of cases and controls failed to yield a discernible difference 
between both patient groups. Judging from individual foci levels in the different skin 
cells (Figure III.9), this outcome was not unexpected since a significant proportion of 
foci levels of cases and controls overlapped one another. Perhaps, prior to rejecting the 
hypothesis that in vivo cellular responses measured in human skin predict for radiation-
induced skin effects, it is pertinent to consider if the patients selected in this study were 
indeed representative of their assigned phenotype. At the outset, this study was 
designed to recruit cases representing the 5% most damaged individuals among a 
cohort of approximately 1000 patients on follow-up, from whom controls have been 
highly selected [13, 14]. Clinical determinants of radiation-induced late changes in the 
breasts were also considered during patient selection such that on the basis of these 
clinical factors alone, cases and controls would have a predicted low and high risk of 
late adverse events following breast radiotherapy, respectively, thereby implying that 
their clinical phenotype rightly reflects their intrinsic radiosensitivity. As it turns out, 
Figure III.13 Individual residual foci levels in blood lymphocytes of 17 cases, stratified 
according to an arbitrary clinician-defined grading of late radiation-induced effects in the 
breast (Figures III.10, 11). Horizontal lines represent patient-averaged foci levels for all cases 
classified within the same group. R2 value was generated using Spearman’s rank correlation 
test with corresponding p-value indicated in brackets.
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strict adherence to the stipulated criteria was extremely difficult to ensure, which is in 
part due to the low prevalence of clinically radiosensitive individuals, even among 
breast radiotherapy patients who had been closely monitored over a prolonged period 
of time. Nonetheless, it was equally important that treatment characteristics remained 
balanced between both patient groups. All things considered, it is unlikely these clinical 
factors could have confounded the selection of cases and controls and in turn, obscured 
a relationship between in vivo DSB repair and radiation-induced late effects in the skin.
Conversely, residual foci levels (24 hours post-4 Gy) in ex vivo irradiated G0 blood 
lymphocytes of cases were significantly higher compared to controls, albeit this 
comparative analysis was performed in a subset of cases and controls from the original 
cohort of 35 patients. Among these patients, foci levels shortly after irradiation (0.5 
hour post-0.5 Gy) did not vary between them. On this basis, it is within reason to 
attribute the difference in residual foci levels between cases and controls to inter-
individual variation in DSB repair processes. Along with existing literature, the 
findings of this study also support the notion of testing cellular end-points in 
lymphocytes as predictive markers of clinical radiosensitivity [10–12, 18].
Strikingly, although a fixed dose of irradiation was delivered to skin and blood 
lymphocytes of the same patients, scoring of residual foci levels 24 hours post-
irradiation were significantly higher in the latter cell type (Patient-average foci per cell 
= 11.32 in blood lymphocytes versus 3.14 in dermal fibroblasts, 3.06 in endothelial 
cells, 2.51 in superficial keratinocytes, and 2.63 in basal epidermal cells, p < 0.001, 
ANOVA). While this may suggest that DSB repair is influenced by tissue environment, 
in this case, skin, the higher number of residual foci in ex vivo irradiated blood 
lymphocytes compared with in vivo irradiated skin cells could actually, for the most 
part, be explained by different experimental conditions rather than cell-specific 
characteristics. In mice, a comparison of DSB repair between ex vivo and in vivo 
irradiated blood lymphocytes revealed slightly higher levels of residual foci after ex 
vivo exposure [19]. Separately, the use of different radiation sources, tissue processing, 
and immunostaining protocols could also collectively contribute to the detection of 
lower residual foci levels in skin cells.
A number of interesting observations were made from tests of association between 
residual foci levels and clinical severity of late effects among cases. Using an 
unconventional grading system generated on the bases of clinical and photographic 
scores for radiation-induced changes in the breast, ten cases were considered the least 
severe (‘Grade 1’), while four and six patients were deemed to be moderate (‘Grade 2’) 
and most severe (‘Grade 3’) cases, respectively. The clinical impression at the time of 
patient stratification was that cases presenting with ‘Grade 2 and 3’ symptoms in our 
study likely represent the 1% and 0.1% most damaged individuals, respectively. Whilst 
it is important to highlight the blinding processes undertaken to ensure an unbiased 
sub-classification of cases, it is also prudent to note that these analyses were simply 
exploratory, and any observed measure of association must be perceived with a 
generous level of caution. Nonetheless, there are two findings of worthy mention 
arising from this exploratory analysis. Firstly, although the process of cases 
stratification may seem subjective, the fact that grading of cases concurred between 
two independent assessments suggests for an element of objectiveness in this scoring 
system. Moreover, through photographic comparisons pre- and post-radiotherapy, 
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clinicians were not simply limited to conventional normal tissue end-points in their 
assessment of late radiation-induced effects, but rather, other parameters such as 
breast shrinkage and shape, which are indicative of fat necrosis and tissue atrophy 
following radiation exposure, were also integrated in the determination of clinical 
radiosensitivity. In support, the robustness of such a method of assessment had been 
tested and validated in a large randomised study of 1410 patients [13]. Secondly, 
positive associations were observed between clinical severity and residual foci levels in 
blood lymphocytes, dermal fibroblasts, and endothelial cells for the same cases, albeit 
statistical significance was not reached for endothelial cells. Closer scrutiny of 
individual foci levels (Figures III.11, 13) suggests that these positive associations were 
mostly a result of extremely high levels of residual foci among a select few cases bearing 
‘Grade 2 and 3’ symptoms. Considering the relevance of dermal fibroblasts and 
endothelial cells in the pathology of late skin fibrosis and telangiectasia, respectively, 
these observations do suggest a role for residual DNA damage following irradiation of 
the skin dermis in the pathogenesis of late radiation-induced skin effects, at least in a 
small cohort of severely radiosensitive patients harbouring an impaired DSB cellular 
phenotype.
III.2.6 Conclusions
In conclusion, the findings of this study propose that ex vivo DSB repair of irradiated 
blood lymphocytes may be more useful than in vivo DSB repair of irradiated skin 
tissues in predicting normal tissue responses in patients following breast radiotherapy. 
In a small subset of extremely radiosensitive individuals, residual DNA damage may 
have a role in the pathogenesis of late adverse effects, at least in the human skin.
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III.3 RESIDUAL DNA AND CHROMOSOMAL DAMAGE IN EX VIVO 
IRRADIATED BLOOD LYMPHOCYTES CORRELATED WITH LATE 
NORMAL TISSUE RESPONSES TO BREAST RADIOTHERAPY
III.3.1 Abstract
To test the association of DSB repair and chromosomal radiosensitivity in ex vivo 
irradiated blood lymphocytes with late-onset normal tissue responses following breast 
radiotherapy. Patients with minimal (controls) or extremely marked late radiotherapy 
changes (cases with ‘grade 2/3’ clinical reactions) were selected from our cohort of 
35 breast radiotherapy patients. DSB induction and repair were quantified by 
γ H2AX/53BP1 immunofluorescence microscopy 0.5 and 24 hours after exposure of G0 
blood lymphocytes to 0.5 and 4 Gy X-rays, respectively. Chromosomal aberrations 
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were scored in blood lymphocyte metaphases after 6 Gy X-rays. Despite similar foci 
levels at 0.5 hour in cases (n = 7) and controls (n = 7), foci levels 24 hours after 4 Gy 
irradiation differed significantly between them (Foci per cell were 12.8 in cases versus 
10.2 in controls, p = 0.004). Increased chromosomal radiosensitivity was also observed 
in cases (Aberrations per cell were 5.84 in cases versus 3.79 in controls, p = 0.001), with 
exchange and deletion type aberrations contributing equally to the difference between 
cases and controls. Residual foci correlated with formation of deletions (Spearman’s 
R = 0.589, p = 0.027) but not exchanges (R = 0.367, p = 0.197) in blood lymphocytes 
from the same patients. The higher levels of exchange type aberrations observed 
among radiosensitive breast cancer patients suggest a role for DSB misrepair, in 
addition to residual DNA damage, as determinants of late normal tissue damage. 
Separately, correlation of residual foci levels with deletion type aberration yields in the 
same cohort confirms their mechanistic linkage.
III.3.2 Introduction
In a small subset of patients, manifestations of radiation-induced late normal tissue 
damage can be significantly marked and potentially physically debilitating. While 
mechanisms underlying late normal tissue effects following exposure to radiotherapy 
remain unclear, it is probable that a combination of various molecular processes are 
involved in the pathogeneses of these late effects. A suitable example illustrating this 
would be the activation of myofibroblasts by TGFβ1 in the pathogenesis of radiation-
induced fibrosis, where activation of TGF β1 following radiation exposure could result 
from either direct activation by reactive oxygen species or through a series of 
transcriptional responses to DNA damage [1, 2]. Given the complexity of pathogenetic 
mechanisms involved in the development of radiation-induced late normal tissue 
damage, it is not surprising that studies looking at predictive markers of clinical 
radiosensitivity have so far yielded conflicting results [3–12]. Of the proposed assays to 
date, single nucleotide polymorphism analysis [7–10], colony forming [13, 14], DSB 
repair [15, 16], lymphocyte apoptosis [17, 18], and chromosomal aberration assays [3, 
4] are few which had shown modest correlations with clinical phenotype.
Within our cohort of 35 breast radiotherapy patients, we had identified a small 
subset of extremely radiosensitive individuals whom had significantly high levels of 
residual DNA damage in skin and blood lymphocytes 24 hours after 4 Gy in vivo and 
ex vivo irradiation, respectively. In this study, we aimed to compare the efficiency of 
DSB repair and chromosomal radiosensitivity in ex vivo irradiated blood lymphocytes 
of these severe cases and matched controls. As this was a subset analysis, we adopted 
the strategy of recruiting only the most informative cases with the intent of detecting 
the maximum difference in cellular responses between cases and controls.
III.3.3 Materials and methods
III.3.3.1 Selection of severe cases and controls
Among our cohort of 20 cases, 10 cases were considered extremely severe (‘Grade 2/3’, 
Figures III.10, 11, 13) based on clinical and photographic assessments of pre- and post-
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radiotherapy changes in their breast, conducted independently by two experienced 
clinical oncologists (JY and NS). Of these cases, seven agreed for repeated blood 
sampling over an 18-month period. Seven carefully matched controls with minimal/no 
late effects were then selected from our original cohort of 15 controls for comparison. 
Ethical approval for the study was obtained from the research ethics committees from 
all the participating centres. Informed consent was obtained from the patients prior to 
participation.
III.3.3.2 Isolation, ex vivo irradiation, and γ H2AX/53BP1 co-immunostaining of G0 
blood lymphocytes
Separation of G0 blood lymphocytes from peripheral blood samples was performed as 
described earlier (Chapter III.2.3.3). After washings with Hank’s buffered solution, 
cells were exposed to 0.5 and 4 Gy using 250 kV X-rays delivered at 0.5 Gy/minute 
(AGO X-ray Ltd, Reading, UK). They were then incubated in minimum essential 
medium, supplemented with 1% L-glutamine, 1% streptomycin, and 10% fetal calf 
serum, at 37°C, 5% CO2 for 0.5 (0.5 Gy) and 24 hours (4 Gy) prior to immunostaining. 
γ H2AX/53BP1 co-immunostaining in blood lymphocytes was performed as previously 
described in Chapter III.2.3.4. A minimum of 50 cells were scored for co-localising 
γ H2AX/53BP1 foci per patient sample.
III.3.3.3 Chromosomal radiosensitivity in blood lymphocyte metaphases after ex 
vivo irradiation
Heparinised whole blood (0.4 ml) diluted in minimum essential medium supplemented 
with 20% fetal calf serum, was irradiated to 6 Gy using 250 kV X-rays delivered at 0.5 
Gy/minute. Irradiated blood was then incubated with 2% phytohaemagglutinin 
(Invitrogen, Paisley, UK) and 0.05 μg/ml colcemid (Sigma-Aldrich, Dorset, UK) at 
37°C, 5% CO2 for 72 hours before hypotonic treatment with 0.075 M potassium 
chloride, fixation in methanol:acetic acid (3:1), slide making by conventional 
techniques, and staining in 2% Giemsa (VWR International Limited, Poole, UK) 
prepared in pH 6.8 buffer. Slides were mounted in Shandon medium (ThermoScientific, 
Hertfordshire, UK) and visualized under light microscopy. Between 50 to 75 metaphase 
spreads per patient were analysed for exchange (dicentrics and rings) and deletion 
(excess acentric fragments) type aberrations. Examples of exchanges and deletions are 
illustrated in Figure III.14.
III.3.3.4 Statistical methods
Blinding processes as elaborated in Chapter III.2.3.5 were similarly applied to 
peripheral blood samples of cases and controls in this sub-group analysis. Comparative 
analyses of foci and chromosomal aberration levels between cases and controls were 
performed using the Mann-Whitney U test. Spearman’s rank correlation test was used 
to test for correlation of foci and chromosomal aberration levels for the same patients. 
All statistical calculations were performed using SPSS version 15.0. To account for the 
small study sample size and multiple statistical comparisons, statistical significance 
was set at a p-value of < 0.01.
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III.3.4 Results
III.3.4.1 Patients
Clinical parameters of the seven selected cases and controls are summarized in Table 
III.5 (presented at the end of Results). Median age of cases and controls were 69 and 67 
years, respectively. Median time of follow-up was 9 and 16 years for cases and controls, 
respectively.
III.3.4.2 γ H2AX/53BP1 foci levels in cases and controls
Comparable foci levels were observed between cases and controls 0.5 hour after 0.5 Gy 
X-rays. In contrast, foci levels 24 hours after 4 Gy X-rays were significantly higher in 
cases compared to controls. Mean foci levels per cell were 7.89 in cases and 8.25 in 
controls 0.5 hour after 0.5 Gy X-rays (p = 0.097), and 12.78 in cases and 10.15 in 
controls 24 hours after 4 Gy X-rays (p = 0.004, Figure III.15).
Figure III.16 shows individual foci levels at both dose- and time-points for all 
patients. Low inter-individual variation of foci levels 0.5 hour after 0.5 Gy was observed 
for all cases and controls, with a coefficient of variation of 5.0%. Inter-individual 
variation of foci levels 24 hours after 4 Gy was significantly higher, specifically among 
cases. Coefficients of variation were 16.8% in cases and 7.7% in controls. All cases, 
with the exception of one, had higher levels of foci 24 hours after 4 Gy compared to 
controls.
Figure III.14 Examples of exchange type aberrations (solid arrows) and acentric fragments 
(open arrows) in blood lymphocyte metaphases following exposure to 6 Gy X-rays ex vivo. 
Each exchange is associated with an acentric fragment and excess acentric fragments are then 
considered as deletions. In this metaphase spread of 46 chromosome pairs, seven exchanges 
comprising of two tricentrics (considered as four dicentrics with four associated acentric 
fragments), two dicentrics (with two acentric fragments), a centric ring (with an acentric 
fragment), and two deletions were scored.
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III.3.4.3 Chromosomal aberration levels in cases and controls
Increased chromosomal radiosensitivity was observed in cases compared to controls 
after 6 Gy X-rays (Figure III.17). Mean aberrations per cell were 5.84 in cases and 3.79 
in controls (p = 0.001). Exchange and deletion type aberrations were on average higher 
in cases. Mean exchanges per cell were 2.74 in cases and 1.83 in controls (p = 0.017), 
and mean deletions per cell were 3.10 in cases and 1.95 in controls (p = 0.026).
Figure III.15 Patient-averaged foci levels in irradiated G0 blood lymphocytes for cases and 
controls. Error bars represent one standard deviation.
Figure III.16 Foci levels in blood lymphocytes 0.5 hour after 0.5 Gy and 24 hours after 4 Gy 
X-rays for the same patients, ordered according to ascending foci levels in blood lymphocytes 
24 hours after 4 Gy.
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Figure III.18 shows individual exchange and deletion type aberration levels after 6 
Gy X-rays for all patients. Between cases and controls, exchanges and deletions 
contributed equally to the overall increase of chromosomal radiosensitivity in cases. 
Notably, all cases had higher total aberration yields than controls.
III.3.4.4 Association between residual foci in G0 lymphocytes and chromosomal 
aberrations in lymphocyte metaphases
Residual foci levels 24 hours after 4 Gy X-rays correlated with levels of chromosomal 
aberrations measured 72 hours after 6 Gy X-rays for the same patients (Spearman’s 
Figure III.17 Patient-averaged chromosomal aberration levels in blood lymphocyte meta-
phases after exposure to 6 Gy X-rays ex vivo. Error bars represent one standard deviation.
Figure III.18 Individual levels of deletions, exchanges, and total aberrations for all patients.
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R = 0.719, p = 0.004). Separate tests of association suggested a patient-specific 
association between residual foci and deletion type aberrations (Spearman’s R = 0.589, 
p = 0.027) but not exchange type aberrations (Spearman’s R = 0.367, p = 0.197, Figure 
III.19).
III.3.5 Discussion
Comparative analyses of DSB repair and chromosomal radiosensitivity in ex vivo 
irradiated blood lymphocytes between women whom had displayed either extremely 
marked or minimal late radiotherapy changes in their breast indicated higher levels of 
residual DNA and chromosomal damage among the clinically radiosensitive patients. 
Exchange or deletion type aberrations contributed equally to the overall increase in 
chromosomal radiosensitivity for this group of patients. Residual γ H2AX/53BP1 foci 
24 hours after 4 Gy in G0 blood lymphocytes were correlated with chromosomal 
aberrations after 6 Gy in blood lymphocyte metaphases for the same patients. 
Specifically, residual foci correlated with the formation of deletions but not exchanges 
from the same patients.
Limited inter-individual variation of foci levels in ex vivo irradiated blood 
lymphocytes 0.5 hour after 0.5 Gy (Figure III.15) supports the notion of similar yields 
of induced DSB following a fixed dose of radiation, as had been reported in patients 
with rare hyper-radiosensitivity syndromes, non-syndromic cancer patients, and 
healthy controls [19]. Likewise, wide inter-individual variation of DSB repair following 
a fixed test dose of ionizing radiation to human skin from non-syndromic individuals 
is consistent with our findings of significant inter-individual variation of residual foci 
levels in lymphocytes 24 hours after 4 Gy [Chapter III.1, 20]. It is therefore within 
reason to conclude that differences in levels of residual foci between cases and controls 
are indicative of significant differences in DSB repair.
A previous comparison between dose intensities of 3 and 6 Gy for determining in 
vitro chromosomal radiosensitivity of blood lymphocytes had indicated a better 
association between chromosomal radiosensitivity and clinical phenotype if the 
former was measured after 6 Gy irradiation [21]. Using similar irradiation conditions, 
we observed significantly higher levels of chromosomal aberrations in blood 
lymphocyte metaphases among women presenting with marked late radiotherapy 
changes. Interestingly, although all cases had higher overall levels of chromosomal 
aberrations compared to controls following a fixed radiation dose, a detailed 
characterisation of exchange and deletion type aberrations (Figure III.18) indicated 
that individually, cases did not necessarily possess consistently higher levels of 
exchanges and deletions compared to controls, and the increment of chromosomal 
radiosensitivity could be a result of either increased exchange or deletion formation in 
cases.
The association between residual foci in unstimulated blood lymphocytes and 
deletions in blood lymphocyte metaphases for the same patients (Figure III.19) is 
consistent with the notion that deletion type chromosomal aberrations arise from 
unrepaired DSB [22, 23]. Similarly, a lack of association between residual foci and 
exchanges is not unexpected given that residual foci are primarily determined by overall 
DSB repair kinetics, whereas DSB misrepair is implicated in the formation of exchanges. 
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Considered together with the independent contributions of exchanges and deletions to 
the increased chromosomal radiosensitivity of clinically radiosensitive patients, these 
findings suggest a plausible role for DSB misrepair, in addition to residual damage, in 
the development of late normal tissue damage following radiotherapy.
Severe ‘over-reactors’ to radiotherapy are extremely rare, constituting less than 1% 
of non-syndromic individuals [24, 25]. The intention of selecting only cases with 
severely marked late radiotherapy changes inevitably led to the small study numbers 
and limited the statistical robustness of the study. To account in part for this limitation 
of the study, a modest p-value of < 0.01 was set for statistical significance. In spite of 
this strict criterion, differences in residual foci levels and chromosomal radiosensitivity 
between cases and controls remained statistically significant.
A recognised obstacle in the development of reliable assays for predicting clinical 
radiosensitivity remains the wide inter-individual biological variation of radiation 
responses within a non-syndromic cohort of patients [26]. Often, a suitable robust cut-
off point for the prediction of clinical radiosensitivity is not possible given the presence 
of high and low ‘outliers’ from the non-radiosensitive and radiosensitive groups of 
patients, respectively. This phenomenon is similarly evident within our cohort of 14 
breast cancer patients where scatter plots of individual patient data (Figures III.16, 18) 
indicate that levels of residual foci and chromosomal aberrations were only marginally 
higher in some cases compared to controls. This, despite having selected for patients 
who differed significantly in their clinical symptoms, suggests to us the limitations 
associated with single assay studies for predicting clinical radiosensitivity. Perhaps, the 
combination of multiple assays may prove to be a more successful approach eventually.
III.3.6 Conclusions
In conclusion, higher levels of residual DSB and deletion type aberrations in ex vivo 
irradiated blood lymphocytes from clinically radiosensitive breast cancer patients 
support a mechanistic framework involving DSB repair in the development of 
radiation-induced late normal tissue damage. The presence of higher levels of exchange 
type aberrations observed in these radiosensitive patients raises the possibility of DSB 
misrepair influencing late normal tissue responses as an independent mechanism.
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III.4 DSB REPAIR AND INDUCTION OF APOPTOSIS FOLLOWING 
EX VIVO  IRRADIATION OF BLOOD LYMPHOCYTES IN 
RELATION TO LATE NORMAL TISSUE RESPONSES OF BREAST 
RADIOTHERAPY PATIENTS
III.4.1 Abstract
To test if induction of apoptosis following ex vivo irradiation of G0 blood lymphocytes 
correlated with clinical radiosensitivity and DSB repair in breast radiotherapy patients 
and healthy volunteers. Using small molecule inhibitors, we examined the relationship 
between DSB repair and radiation-induced apoptosis. Sixteen breast cancer patients 
with minimal (controls, n = 8) or extremely marked late radiation-induced change 
(cases, n = 8) and eight healthy volunteers were selected. These included the highly 
selected seven cases and controls from the preceding study. DSB were quantified by 
γ H2AX/53BP1 immunostaining, and apoptosis levels were assessed using a fluorogenic 
inhibitor of caspases (FLICA) assay. Apoptotic cells were defined by small cell size and 
positive FLICA signal measured using flow cytometry. DNA-PK (Nu7441) and ATM 
(Ku55933) inhibitors were used at concentrations of 1 and 10 μM, respectively. Mean 
γ H2AX/53BP1 foci levels 24 hours after 4 Gy were higher in cases (12.7) than in controls 
(10.3, p = 0.002). In contrast, the mean proportion of apoptotic cells 48 hours after 
8 Gy was comparable, 37.2% in cases and 34.7% in controls (p = 0.442). Residual foci 
and apoptosis levels were not correlated within individuals (Spearman’s R = –0.0059, 
p = 0.785). However, Nu7441-treated cells had higher foci and apoptosis levels 48 
hours after 1 Gy compared to mock-treated cells, suggesting that apoptosis induction 
following irradiation is modulated by DSB repair. This effect required functional ATM 
since cells treated simultaneously with Nu7441 and Ku55933 were resistant to apoptosis 
despite high levels of residual foci. Among our clinical cases, one displayed an impaired 
DNA-PK-dependent end-joining cellular phenotype. In summary, clinical radio-
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sensitivity may be associated with impaired DSB repair in some patients. Although 
pharmaceutical inhibition of ATM and DNA-PK affected apoptosis induction and 
DSB repair, no association was observed between apoptosis and residual foci levels in 
patients and volunteers.
III.4.2 Introduction
The most common factor limiting dose escalation in radiotherapy treatment of cancers 
remains the risk of late normal tissue effects [1, 2]. Apart from rare instances when 
severe acute reactions result in consequential late effects, often, the onset and severity 
of acute effects are not necessarily predictive of late events occurring months or years 
after treatment [3, 4]. In individuals who lack characteristic phenotypes of rare clinical 
radiosensitivity syndromes, this temporal sequence of clinical changes prevents the 
identification of individuals at elevated risk of severe late toxicities. Recently, a rapid 
lymphocyte-based apoptosis assay has been proposed to predict clinical radiosensitivity 
rather reliably [5, 6]. Stratifying patients according to their in vitro apoptotic responses, 
high levels of radiation-induced apoptosis were predictive of normal responses to 
radiotherapy, while individuals with low levels of apoptosis were likely to be clinically 
radiosensitive. Given that radiation-induced apoptosis is primarily an ATM-mediated 
cellular response to ionising radiation, these findings could be interpreted to fit the 
A-T model where clinical radiosensitivity is a phenotype associated with loss of ATM 
function.
Following exposure to ionising radiation, critical cellular responses to DSB include 
the induction of apoptosis, a form of programmed cell death triggered largely by 
the recruitment and activation of ATM protein at these break sites. ATM-mediated 
apoptosis occurs primarily through controlling post-translational modifications 
of p53 and phosphorylation of Mdm2, an ubiquitin ligase which in its native 
unphosphorylated state binds to p53, thereby targeting the tumour suppressor protein 
for degradation [7–9]. In addition, ATM also regulates apoptotic signalling indirectly 
via a redundant pathway involving Chk2 phosphorylation of p53 [10]. Although much 
is known about the signalling events surrounding ATM-mediated induction of 
apoptosis, the mechanistic regulation between DNA damage signalling and cell death 
following exposure to ionising radiation is unclear. Lately, it has been suggested that 
the balance between these cellular processes is governed by the phosphorylation of 
serine 139 and tyrosine 142 on H2AX. Phosphorylation of H2AX on serine 139 
(γ H2AX), most notably by ATM, promotes the recruitment and accumulation of 
MDC1 and other damage signalling proteins, while phosphorylation on tyrosine 142 
by the kinase activity of Williams-Beuren syndrome transcription factor (WSTF) 
prevents MDC1 focus formation and instead promotes binding to pro-apoptotic 
proteins, such as JNK1 [11–14]. Concerning DSB repair and induction of cell death, 
early experimental data had long implicated the presence of persistent DNA damage 
as a trigger of apoptosis, supporting a mechanistic linkage between these cellular end-
points [15]. Nonetheless, the validity of this notion was recently brought into question 
on the basis of laboratory findings demonstrated in wild-type thymocytes where 
inhibition of DNA-PK-dependent end-joining failed to modulate levels of apoptosis 
despite high levels of residual DNA damage in these cells [16].
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In this study, DSB repair and apoptosis induction in ex vivo irradiated blood 
lymphocytes were assessed as markers of normal tissue radiosensitivity in 16 women 
selected on the basis of late adverse effects to breast radiotherapy. With the inclusion of 
a further eight healthy individuals, we proceeded to test the relationship between these 
cellular responses within our cohort of radiotherapy patients and volunteers using 
small molecule inhibitors of DNA-PK and ATM kinase.
III.4.3 Materials and methods
III.4.3.1 Severe cases, controls, and healthy volunteers
Eight cases and controls, including the seven severe cases and controls from the 
preceding study, were recruited. Median age of cases and controls was 66 and 67.5 
years, respectively. Median duration of follow-up for cases and controls was 8 and 14.5 
years, respectively. Eight healthy volunteers were also accrued for the study. Age of 
healthy volunteers ranged from 25 to 64 years. Ethical approval for the study was 
obtained from research ethics committees at all participating centres. Informed 
consent was obtained from the patients and healthy volunteers prior to participation.
III.4.3.2 Ex vivo irradiation and immunostaining of G0 blood lymphocytes
G0 blood lymphocytes were isolated from whole blood using similar protocols (Chapter 
III.2.3.3). Blood lymphocytes were irradiated using 250 kV X-rays delivered at 0.5 Gy/
minute (AGO X-ray Ltd, Reading, UK), and immunofluorescence staining was 
performed as previously described at selected time-points (Chapter III.2.3.4). The 
following primary antibodies were used for immunostaining: anti-53BP1 (mab3802, 
Millipore, Watford, UK, 1:400 and ab36823, Abcam, Cambridge, UK, 1:400), anti-
γ H2AX (05-636, Millipore, 1:500, ab18311 and ab26350, Abcam, 1:500), and anti-
phosphoS1981-ATM (ab81292, Abcam, 1:100). Appropriate secondary antibodies 
were conjugated with Alexa-Fluor 488, 555, and 594 (Invitrogen, Paisley, UK, 1:200). 
Co-localising γ H2AX/53BP1 foci were scored in a minimum of 50 cells per slide for 
each patient sample.
III.4.3.3 Radiation-induced apoptosis in irradiated G0 blood lymphocytes
Radiation-induced apoptosis was assessed using a carboxyfluorescein fluorochrome 
inhibitor of caspases assay (FLICA, AbD Serotec, Oxford, UK). Blood lymphocytes 
were incubated with FLICA (1:150) for 1 hour prior to irradiation, and the proportion 
of apoptotic cells was measured by flow cytometry 48 hours following exposure to 
X-rays. Apoptotic cells were defined by small cell size and positive cellular FLICA 
uptake. For apoptosis measurements in CD8 and CD4 T-lymphocyte subsets, cells 
were further incubated with anti-CD8 (ab4055, Abcam, 1:100) and anti-CD4 (ab1046, 
Abcam, 1:100) antibodies for 1 hour, washed with PBS, and incubated with appropriate 
secondary antibodies conjugated with Alexa-Fluor 660 (Invitrogen, Paisley, 1:200) for 
1 hour. Following final washes, lymphocytes were analysed using a Millipore Guava 
EasyCyte flow cytometer (Millipore UK Ltd, Watford, UK). Information was obtained 
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from 10,000 lymphocytes per sample and characterised by cell size, granularity, and 
fluorescent signal intensity using Guava InCyte software (Millipore UK Ltd, Watford, 
UK).
III.4.3.4 Treatment with small molecule inhibitors
Blood lymphocytes were treated with Nu7441 and Ku55933 to inhibit the activity of 
DNA-PK and ATM, respectively. Drugs were purchased from Tocris Bioscience, 
Bristol, UK, reconstituted in DMSO as 10 mM stocks, and stored in –20°C. Nu7441 
and Ku55933 were added to lymphocytes for 1 hour prior to irradiation and kept in situ 
until harvest at concentrations of 1 (0.01% DMSO) and 10 μM (0.1% DMSO), 
respectively. All results were compared against controls incubated with 0.1% DMSO 
alone.
III.4.3.5 Statistical methods
Blinding processes as elaborated in Chapter III.2.3.5 were similarly applied to 
peripheral blood samples of cases and controls in this study. Comparative analyses of 
foci and apoptosis levels between cases and controls were performed using the Mann-
Whitney U test. Spearman’s rank correlation test was used to test for correlation of foci 
and apoptosis levels for the same individuals. All statistical calculations were performed 
using the statistical software SPSS version 15.0. Given the small sample size, statistical 
significance was set at a modest p-value of < 0.01.
III.4.4 Results
III.4.4.1 Increased γ H2AX/53BP1 foci levels 24 hours after 4 Gy in cases compared to 
controls
Significant inter-individual variation of foci levels in G0 blood lymphocytes 24 hours 
after 4 Gy was observed for cases and controls (coefficient of variation of the entire 
cohort was 16.9%). Compared to controls, foci levels were higher in all cases, with the 
exception of one. Mean foci per cell were 12.7 in cases and 10.3 in controls (Figure 
III.20, p = 0.002).
III.4.4.2 Comparable apoptosis levels 48 hours after 8 Gy between cases and controls
Among cases and controls, there was significant inter-individual variation of apoptosis 
levels in G0 blood lymphocytes 48 hours after 8 Gy (coefficient of variation of the 
entire cohort was 30.4%). In contrast to residual foci levels 24 hours after 4 Gy, 
similar mean levels of apoptosis were observed in cases (37.2%) and controls (34.7%, 
p = 0.442, Figure III.21).
Apoptosis levels in the CD8 and CD4 T-lymphocyte subsets were also comparable 
between them. Mean proportion of CD8 and CD4 apoptotic cells was 37.7% in cases, 
38.3% in controls (p = 0.721) and 23.6% in cases, 23.8% in controls (p = 0.878, Figure 
III.22), respectively.
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III.4.4.3 Induction of apoptosis is dependent on DSB end-joining and ATM kinase 
activation in G0 blood lymphocytes
A test of association indicated that apoptosis levels 48 hours after 8 Gy were not 
correlated with residual foci levels 24 hours after 4 Gy in G0 blood lymphocytes 
of radiotherapy patients and healthy volunteers (Figure III.23, Spearman R = –0.059, 
p = 0.785).
Figure III.20 Individual foci levels in G0 blood lymphocytes of cases and controls 24 hours 
after 4 Gy X-rays ex vivo. Horizontal lines represent patient-averaged foci levels.
Figure III.21 Apoptosis levels in G0 blood lymphocytes 48 hours after 8 Gy X-rays ex vivo in 
cases and controls. Horizontal lines represent patient-averaged levels of apoptosis.
DSB repair and apoptosis in radiosensitive patients 77
To determine if apoptosis levels were modulated by DSB signalling, we proceeded to 
measure apoptosis levels in ex vivo irradiated G0 blood lymphocytes treated with 
Nu7441 for the purpose of inhibiting DNA-PK-dependent end-joining in these cells. 
Figure III.24 illustrates the foci levels measured at different times (1, 2, 4, 24, and 48 
hours) after 1 Gy in mock- and Nu7441-treated cells of a healthy volunteer. At 48 hours 
post-irradiation, 73% of DSB were repaired in mock-treated cells in contrast to 
Nu7441-treated cells where only 33% of DSB were repaired, thereby confirming the 
Figure III.22 Patient-averaged levels of apoptosis in CD8 and CD4 T-lymphocyte subsets of 
cases and controls. Error bars represent one standard deviation.
Figure III.23 Foci levels 24 hours after 4 Gy and levels of apoptosis 48 hours after 8 Gy in 
X-irradiated G0 blood lymphocytes of radiotherapy patients and healthy volunteers. Line 
and R2 value were generated using linear regression and Spearman’s rank correlation test, 
respectively, with corresponding p-value indicated in brackets.
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efficacy of Nu7441. In addition, modulation of ATM-driven induction of apoptosis in 
irradiated G0 blood lymphocytes was also tested by treating these cells with Ku55933, 
an ATM kinase-specific small molecule inhibitor. To validate the efficacy of Ku55933, 
we confirmed the absence of phosphorylated ATM in irradiated G0 blood lymphocytes 
following treatment with Ku55933, as well as the failure to observe γ H2AX/53BP1 foci 
formation post-irradiation when cells were treated with a combination of Ku55933 
and Nu7441 (Figure III.25).
In accordance with the increased residual foci levels in Nu7441-treated cells, we 
observed significantly higher levels of apoptosis in these cells compared to mock-
treated controls 48 hours after 1 Gy (Figure III.26). However, when ATM was inhibited 
simultaneously using Ku55933 in these cells, low levels of apoptosis, comparable to 
levels in cells treated with Ku55933 alone, were observed. Experimental repeats in 
cases and controls were consistent with observations in healthy volunteers (Figure 
III.27).
III.4.4.4 Impaired DSB repair cellular phenotype in a case with severe clinical 
radiosensitivity
Of the cases in our cohort, we identified an individual with an exceptionally severe 
phenotype who had markedly elevated levels of residual foci in G0 blood lymphocytes 
24 hours after 4 Gy (mean foci per cell = 16.3, Figure III.20). The foci level in this 
patient was highest among all in the study cohort and at least 1.5-fold higher compared 
to controls. Figure III.28 illustrates foci levels measured at different times (1, 2, 4, 24, 
and 48 hours) after 1 Gy in G0 blood lymphocytes of this unique case and a control. 
Figure III.24 Foci levels at different times post-1 Gy X-irradiation in mock- and Nu7441-
treated cells. Error bars represent one standard error of mean of three independent experiments. 
Abbreviation = IR, irradiation.
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The control was selected on the basis of scoring for the lowest level of residual foci 
among the breast cancer patients. Four hours following irradiation, a 21.5% difference 
in foci levels was observed between case and control and the difference increased to 
46.3% 48 hours post-irradiation, confirming a slower rate of DSB repair in this 
individual.
To broadly determine the impaired DSB repair process in this severely radiosensitive 
individual, we designed a series of experiments based on the following principle. In 
non-cycling G0 blood lymphocytes where NHEJ is the primary mode of DSB repair, 
ATM and DNA-PK have been determined to be key drivers of the slow and fast 
components of a bi-exponential model of DSB end-joining, respectively [17, 18]. 
Hence, depending on the pathway (slow/fast repair) contributing to the difference in 
foci levels post-irradiation between our case and control, inhibition of the involved 
process should in theory abolish any observed difference in foci levels between them, 
indirectly implying that the inhibited pathway is the source of the impaired DSB repair 
phenotype in this radiosensitive patient. To this end, foci measurements were repeated 
in G0 blood lymphocytes of the same case and control at identical time-points after 1 
Gy X-irradiation. Separately, cells of both patients were also treated with Ku55933 or 
Nu7441 to inhibit ATM kinase or DNA-PK activity, respectively.
Figure III.25 Ku55933 and a combination of Ku55933 and Nu7441 affected radiation-induced 
foci formation of phosphorylated ATM (pATM) and γH2AX/53BP1, respectively. Scale = 10 μm. 
Abbreviation = IR, irradiation.
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Figure III.29 illustrates the foci levels in irradiated lymphocytes of case and control 
following mock, Ku55933, and Nu7441 treatment. Expectedly, inhibition of ATM and 
DNA-PK affected rates of foci loss in both case and control, as evident by the higher 
levels of foci scored in drug-treated cells compared to cells which were not exposed to 
the kinase inhibitors. However, unlike after ATM inhibition where foci levels remained 
higher in cells of the clinically radiosensitive individual (upper panel, Figure III.29), 
comparable foci decay kinetics were observed between case and control following 
Figure III.26 G0 blood lymphocytes were irradiated with 1 Gy X-rays following treatment 
with 0.1% DMSO (mock), Nu7441, Ku55933, or a combination of Nu7441 and Ku55933. 
Percentages of apoptotic cells were assessed 48 hours post-IR using the FLICA assay and 
measured by flow cytometry. Percentages of apoptotic cells (small cell size and positive FLICA 
signal) are as indicated. Abbreviation = IR, irradiation.
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Figure III.27 Repeats of the experiments shown in Figure III.26 were performed in two cases, 
controls, and healthy volunteers. Bar plots indicate patient-averaged percentages of apoptotic 
cells corrected for levels in unirradiated mock- or drug-treated samples. Error bars represent 
one standard deviation. Abbreviation = IR, irradiation.
Figure III.28 Foci levels at different time-points over 48 hours after 1 Gy X-irradiation in 
G0 blood lymphocytes of a severely radiosensitive case and control. Error bars represent one 
standard error of mean of three independent experiments. Abbreviation = IR, irradiation.
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inhibition of DNA-PK activity (lower panel, Figure III.29), suggesting that in this 
specific patient, fast component DSB end-joining may be impaired.
III.4.5 Discussion
A study of DSB repair and induction of apoptosis in ex vivo irradiated G0 blood 
lymphocytes of breast radiotherapy patients revealed higher levels of residual 
γ H2AX/53BP1 foci among highly selected individuals with marked late adverse effects 
Figure III.29 Foci levels after 1 Gy irradiation in mock- or drug-treated G0 blood lymphocytes 
of the severe case and control. Error bars represent one standard error of mean of three 
independent experiments. Abbreviation = IR, irradiation.
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of breast radiotherapy compared to controls, but comparable levels of apoptosis 
between them. Among the most severely affected cases was an individual with the 
highest levels of residual DNA damage in blood lymphocytes 24 hours after 4 Gy 
X-irradiation and an impaired DNA-PK-dependent DSB end-joining cellular 
phenotype. Supporting the findings ex vivo, foci measurements of in vivo irradiated 
skin of this patient also revealed high levels of residual DNA damage among a cohort 
of 35 breast radiotherapy patients [Table III.1, Patient 32]. In that analysis, foci levels 
24 hours after 4 Gy in epidermal and dermal cells (fibroblasts and endothelium) of this 
patient were on average 1.5-fold higher compared to patient-averaged foci levels of the 
whole cohort. Collectively, these findings suggest an association between clinical 
radiosensitivity and impaired DSB repair in this and perhaps other patients.
We have already reported similar observations of increased levels of residual DNA 
damage among patients presenting with severe late normal tissue effects following 
previous radiotherapy [Chapters III.2 and 3]. The significance of our current findings 
thus stems from the potential identification of an impaired DNA-PK-dependent end-
joining cellular phenotype in a non-syndromic individual. Interestingly, treatment 
records of this patient did not indicate the presence of severe acute skin reactions 
during radiotherapy. Apart from the late adverse effects of radiotherapy, she is well and 
does not harbour clinical features characteristic of a defective DSB end-joining 
phenotype, such as immunodeficiency, developmental delay, or susceptibility to other 
haematological and solid tumours [19]. To investigate the nature of the DSB repair 
impairment, we had explored the use of kinase-specific inhibitors targeted at ATM 
and DNA-PK. The rationale of our experimental design was based on the idea that 
inhibition of the impaired DSB repair process in this clinically radiosensitive individual 
and likewise in a control would abolish any difference in repair kinetics between both 
subjects. Although the study findings suggest that DNA-PK-dependent DSB end-
joining is affected in this unique individual, some limitations associated with this 
experimental approach ought to be highlighted. Foremost, a key flaw with the 
experimental design stems from the reliance on γ H2AX/53BP1 foci formation as the 
surrogate of DSB repair. Despite the fact that ATM and DNA-PK have been established 
to partake in the phosphorylation of H2AX with some degree of functional redundancy 
between both pathways [20], it is uncertain if inhibiting either kinases would have 
altered the read-out of a γ H2AX/53BP1 foci assay. To augment and validate our study 
findings, it is therefore necessary to repeat the experiments using DSB repair assays 
such as pulsed field electrophoresis or the comet assay where assay read-outs are 
independent of ATM and DNA-PK phosphorylation of H2AX. As such, one could 
argue that on the basis of our study findings alone, there is no conclusive evidence to 
support the proposal of a novel DNA-PK-dependent DSB repair defect in this unique 
patient. Moreover, the broad and perhaps crude nature of our experimental design did 
not allow for the identification of a specific defect within the NHEJ signalling cascade. 
To investigate further, we have henceforth embarked on exome sequencing of genes 
encoding for proteins relevant to NHEJ in this patient. Hopefully, through these 
analyses, we are able to derive further definitive evidence supporting a novel DNA-PK-
dependent DSB end-joining defect in this clinically radiosensitive individual.
Comparative analysis of radiation-induced apoptosis in blood lymphocytes 
between cases and controls did not reveal a difference. Additional analyses of apoptosis 
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in specific T-lymphocyte subsets also indicated a lack of difference between the patient 
groups. Although experimental conditions, such as irradiation dose and time-point, 
were consistent between this and previous reports showing a correlation between 
lymphocyte apoptotic responses and clinical radiosensitivity [5, 6], it is perhaps 
noteworthy that a different assay was adopted for assessing apoptotic lymphocytes 
in this current study. In the studies performed by Azria and colleagues, apoptosis 
induction was measured through quantification of the proportion of a distinct 
population of cells bearing features of a small cell size and significant subgenomic 
DNA content, while the assay described in this report utilises the presence of caspase 
activation as a surrogate for induction of apoptosis following radiation exposure. 
A plausible explanation for the discrepancy in study findings could then relate to 
the variation in experimental end-points, particularly since caspase-independent 
mechanisms of apoptosis induction would not have been captured with the latter assay 
[21]. In this regard, it would be necessary to validate our assay against conventional 
apoptosis assays designed to test for cellular morphological changes associated with 
apoptosis, such as terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) and test of annexin A5 affinity. Individually, these assays measure DNA 
fragmentation and loss of plasma membrane asymmetry, respectively. Separately, it 
is also known that assays of radiation-induced apoptosis are exquisitely liable to 
multiple physiological sources of variation [22]. It is therefore also possible that subtle 
experimental variations such as the use of an isolation procedure to derive blood 
lymphocytes from whole blood samples and small sample cohorts explained the failure 
to detect differences between cases and controls as reported by Azria and colleagues.
Although pharmacological inhibition of DNA-PK-dependent end-joining in G0 
blood lymphocytes reduced DSB repair and enhanced apoptosis induction, residual 
foci and apoptosis levels were not correlated in the same radiotherapy patients and 
healthy volunteers. Our experimental findings suggest that apoptosis is a process 
dominated by ATM kinase activation (Figure III.26), whereas NHEJ in G0 blood 
lymphocytes is largely driven by DNA-PK and to a lesser extent, ATM (Figure III.29). 
Taken together, the lack of correlation between residual foci and apoptosis levels in 
our cohort could conceivably be explained by inter-patient variation in ATM protein 
levels or kinase function. In a recent study by Fang et al., quantitative analyses of ATM 
levels among a cohort of breast cancer patients revealed significant inter-patient 
differences of up to 12.5-fold, which would be consistent with this notion [23].
A separate point of difference raised from our experimental findings is the 
modulation of apoptosis levels following inhibition of DSB repair, contrasting recent 
findings by Callén et al [16]. In their study, induction of apoptosis was monitored by 
caspase 3 activation 24 hours after 5 Gy. To address these minor experimental variations 
between both studies, we repeated apoptosis measurements in Nu7441-treated blood 
lymphocytes 24 and 48 hours after 5 Gy. In accordance with our observations 48 hours 
after 1 Gy, apoptosis levels were similarly increased in Nu7441-treated cells 24 and 48 
hours following exposure to a higher radiation dose (Figure III.30).
In light of these conflicting findings, it must be said that the regulation of apoptosis 
in the presence of persistent DNA damage remains open to question. It would be 
interesting to resolve the inter-play of signalling events regulating DSB repair and 
apoptosis given that these processes are largely governed by different protein kinases. 
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Judging from our findings, it is plausible to suggest a mechanistic model involving the 
additional recruitment of ATM to the flanks of these persistent DSB leading to further 
activation of p53-dependent apoptosis since inhibition of ATM phosphorylation 
obliterates this phenomenon [24].
III.4.6 Conclusions
In summary, we have demonstrated that an impaired DSB repair cellular phenotype 
may be associated with clinical radiosensitivity in some radiotherapy patients 
presenting with severe late normal tissue effects. Nonetheless, the small sample size of 
this study precludes support for a lymphocyte-based DSB repair assay for predicting 
normal tissue radiosensitivity. Impairment of DSB end-joining increases the propensity 
for cells to undergo apoptosis, but this phenomenon is primarily regulated by an active 
ATM function.
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IV
General discussion
IV.1 PROJECT SUMMARY
A test of DSB repair in healthy skin tissues and primary G0 blood lymphocytes of 35 
breast radiotherapy patients reveals that this cellular process is impaired among a 
subset of clinically radiosensitive patients, in particular, individuals with severely 
marked late effects to breast radiotherapy. Although comparative analyses of residual 
DSB levels between highly selected cohorts of cases (patients with moderate/marked 
radiotherapy changes) and controls (patients with minimal effects to radiotherapy) 
indicated higher levels of residual DSB among the former patient group, this was only 
observed when the assay was applied in ex vivo irradiated blood lymphocytes but not 
in vivo irradiated skin tissues. The disparity in results of these comparisons of patient-
averaged levels of residual DSB could be attributed to observed differences in DSB 
repair between skin cells and blood lymphocytes following exposure to a fixed dose of 
ionising radiation. Between different skin cells in the epidermis and dermis, comparable 
levels of residual DSB were observed 24 hours after irradiation, suggesting that repair 
of cellular DSB is a molecular process independent of cell-specific physiological 
characteristics. Higher levels of cellular DNA damage sustained in blood lymphocytes 
as compared to skin cells despite similar doses of irradiation would propose a 
modifying influence of the tissue microenvironment on DSB repair, although the 
perceived slower rate of DSB repair may be explained in part by experimental variations. 
Taken together, it can be concluded that assessment of cellular responses to ionising 
radiation exposure in blood lymphocytes constitutes a valid cell-based approach to 
predicting normal tissue radiosensitivity, and an in vivo tissue-specific model does not 
appear to be a more robust alternative.
In a subset analysis comprising of only individuals with severe late reactions to 
breast radiotherapy (likely representing the 0.1% and 1% most damaged individuals) 
and matched controls, chromosomal radiosensitivity and radiation-induced apoptosis 
were compared against DSB repair as potential cellular markers of clinical radio-
sensitivity. Higher levels of chromosomal aberrations were uniformly observed in 
blood lymphocyte metaphases of all selected cases compared to controls, a phenomenon 
contributed by the increased formation of both exchange (dicentrics and centric rings) 
and deletion type (excess acentric fragments) aberrations among cases. These findings 
add to the existing literature supporting the application of chromosomal radiosensitivity 
as a biomarker of normal tissue responses to radiotherapy. Separately, the lack of 
correlation between formation of exchanges and levels of residual DSB in the same 
patients further raises the possibility that presence of chromosomal translocations, 
formed as a result of incorrect joining of DSB ends, may have an impact on critical 
tissue responses involved in the pathogeneses of late adverse effects to radiotherapy. 
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Contrary to reported literature, we were unable to demonstrate differences in apoptotic 
responses of irradiated blood lymphocytes between cases and controls. As elaborated 
in the preceding chapter (Chapter III.4.5), this discrepancy could be in part related to 
the use of different apoptosis assays between this and previous reports. Moreover, 
considering the relative size of our patient cohort to the reported studies, it must be 
cautioned that the lack of association between this cellular parameter and clinical 
phenotype bears no implication on the potential usefulness of this assay for predicting 
normal tissue radiosensitivity. It is interesting that levels of apoptosis induction and 
residual DSB were not correlated in irradiated blood lymphocytes of the same 
individuals, although through pharmacological inhibition of DSB repair, it was 
demonstrated that cells harbouring higher levels of DNA damage had an increased 
propensity to undergo apoptosis. Nonetheless, it was also observed that induction of 
apoptosis, even in the presence of significant DNA damage, was hugely reliant on 
ATM kinase activation. It is therefore conceivable that if individuals possess differing 
levels of functional ATM kinase activity, a lack of association between these molecular 
processes within the individual can be expected.
Finally, we highlight a clinically radiosensitive individual who presented to us with 
extremely severe late effects shortly after undergoing breast radiotherapy. Treatment 
parameters for this patient did not include prescription of a high radiotherapy dose or 
other significant unfavourable factors which may have predisposed her to an increased 
risk of late adverse effects. DSB repair assay performed in irradiated skin and blood 
lymphocytes of this patient indicated markedly high levels of residual DSB in these 
tissues, approximately 1.5-fold higher compared to mean DSB levels of the whole 
patient cohort. To broadly characterise the defective molecular pathway leading to 
DSB repair impairment in this individual, G0 blood lymphocytes of this patient and a 
control were treated with small molecule inhibitors of DNA-PK (Nu7441) or ATM 
(Ku55933) to inhibit components of DSB repair relating to DNA-PK-dependent NHEJ 
(fast) or ATM-dependent repair of heterochromatin-related DSB (slow). The rationale 
underlying the design of this assay was such that if the pathway involved was 
simultaneously inhibited in both case and control, similar kinetics of DSB repair 
would be observed in both patients. Based on the findings of these tests, we proposed 
that DNA-PK-dependent NHEJ is impaired in this unique individual. Nonetheless, 
alluding to reasons as discussed earlier (Chapter III.4.5), it is imperative to recognise 
the limitations associated with our experimental design, particularly with regard to 
the possibility of interference of assay end-point read-out. Considering the absence of 
other clinical features associated with a defective DSB repair phenotype in this clinically 
radiosensitive patient, it would be interesting to determine the specific genetic mutation 
or epigenetic modification contributing to this cellular phenotype. Given that NHEJ is 
essentially a multi-step process driven by a variety of proteins, the initial steps of 
identifying the lesion currently involve exome sequencing to characterise the genomic 
composition of the different proteins involved in this repair mechanism. Short of 
clonogenic assessment studies to confirm an increased radiation sensitivity of primary 
cells of this patient, it is within reason to conclude that our findings allude to an 
indirect association between an impaired DSB repair cellular phenotype and clinical 
radiosensitivity, once again, highlighting the pivotal role of this molecular process in 
modulating normal tissue radiosensitivity, as suggested by historical data [1, 2].
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IV.2 CHALLENGES AND CLINICAL IMPACT OF PREDICTIVE 
TESTING OF NORMAL TISSUE DAMAGE
IV.2.1 Controversies of  case-control studies testing for predictive markers of  
normal tissue radiosensitivity
For decades, developing a robust predictive assay of normal tissue radiosensitivity has 
been the subject of intensive research within the radiotherapy community. However, as 
many are also aware, much of these efforts have been rewarded with limited success, 
often confined to small case-control pilot studies. Typically, a promising predictive 
marker of normal tissue radiosensitivity, proposed on the basis of correlation between 
cellular and clinical end-points within a small cohort of radiotherapy patients, fails to 
reproduce comparable levels of association between both parameters when tested in a 
larger and more heterogeneous patient cohort [3–6]. Other times, conflicting results 
would arise from independent studies investigating the same predictive assay of normal 
tissue radiosensitivity, thus questioning the reproducibility and reliability of the tested 
assay [7–10]. As raised in the earlier chapters, the potential to establish a correlation 
between a cellular marker and clinical radiosensitivity is heavily influenced by a 
number of factors [11]. Briefly, these factors include selection of cases and controls 
while ensuring that modifying factors of normal tissue responses are considered, 
adopting an appropriate clinical end-point as an indicator of clinical radiosensitivity, 
quality and consistency of clinical follow-up, employing an assay with a well established 
laboratory protocol, along with choosing the optimal experimental conditions for 
dose, dose rate, time-point, and cell type.
In addition to these factors, flaws pertaining to study designs and result analyses have 
also been proposed for the lack of success of case-control studies testing for predictive 
markers of normal tissue radiosensitivity. Most notably, in a 2003 editorial by Dikomey 
and colleagues from the Hamburg group [12], basing their analysis on data reported by 
Peacock et al. [6], it was elegantly demonstrated that although comparative analysis of 
mean cellular radiosensitivity between cases and controls did not reveal a difference 
between them, a positive association between cellular radiosensitivity and late clinical 
effects may have been observed in that study had the authors undertook a different 
approach with result analysis. Perhaps, before elaborating further, it must be mentioned 
in the same vein that the methods proposed by Dikomey et al. are based on the 
assumption that incidence of late normal tissue effects occurs at a constant annual rate 
in radiotherapy patients across all spectrums of intrinsic radiosensitivity, a concept 
recently put forth by Jung and colleagues [13]. Figure IV.1 provides an illustrative 
explanation of this concept. From this example, it is apparent that ‘resistant’ patients 
are also liable to severe late effects of radiotherapy. In this context, it would be 
unsurprising why comparison of mean cellular radiosensitivity between two groups of 
patients, selected based on their clinical presentation of late adverse effects alone, is 
likely to yield a negative result, since there is a strong possibility that selected ‘cases’ may 
not necessarily correspond to an intrinsically radiosensitive population.
The method of analysis proposed by Dikomey et al. is presented in Figure IV.2. 
Contrary to comparing mean cellular radiosensitivity between cohorts of cases and 
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controls (Figure IV.2, bottom panel), it was suggested that tests of association between 
the predictive test and clinical end-point should be performed on data stratified 
according to individual intrinsic radiosensitivity, as determined by the former (Figure 
IV.2, top and middle panels). Applying this method, it is evident that an association 
exists between both cellular and clinical parameters, given that a higher proportion of 
intrinsically ‘sensitive’ individuals suffers from grade 2/3 reactions, whereas ‘resistant’ 
individuals mostly present with grade 1/no reaction.
Figure IV.1 Kinetics of Grade 3 late effects following radiotherapy based on estimates 
generated from the model proposed by Jung et al. [13]. Data is presented for each patient sub-
group, classified according to their intrinsic radiosensitivity (determined in vitro). For each 
group, proportion of complication-free patients was plotted against time after radiotherapy. 
Dashed line represents kinetics calculated for the entire cohort. Reused with permission from 
Dikomey et al., 2003 [12].
Figure IV.2 Theoretical distribution of ‘resistant’, ‘normal’, and ‘sensitive’ patients in 
relation to clinical severity of late normal tissue effects (grade ≤ 1, 2, 3) calculated partially 
based on plots presented in Figure IV.1 and an assumption of a normal distribution of intrinsic 
radiosensitivity among radiotherapy patients. Data is generated for a follow-up period of 
6 years post-radiotherapy. (Top) Relative fractions of ‘resistant’, ‘normal’, and ‘sensitive’ 
patients with grade ≤ 1, 2, 3 reactions. (Middle) Absolute number of patients (based on a 
cohort of 200 patients) for each category derived from data presented in the top panel. (Bottom) 
Absolute number of patients classified according to their clinical severity. Reiterating an earlier 
point made regarding possible flaws relating to a case-control study design, it is evident that an 
analysis of mean cellular radiosensitivity between cohorts of patients with marked or minimal 
clinical reactions is unlikely to yield a positive difference between them. It is nonetheless 
important to note that this argument is primarily based on the concept that incidence of late 
reactions occurs at a constant annual rate, albeit at different kinetics in individuals of differing 
intrinsic radiosensitivity. Reused with permission from Dikomey et al., 2003 [12].
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At this point, it is probably relevant to address rightful concerns of the methods 
employed in our study. Although a comparative analysis approach was adopted for 
data analyses in the study, additional critical steps pertaining to patient selection were 
undertaken, taking into account some of the arguments presented by Dikomey and 
colleagues. Firstly, cases in the study were chosen among patients who had presented 
with late adverse effects at an early time-point after breast radiotherapy, while it is 
required that controls with minimal symptoms have had a lengthy duration of follow-
up. In selecting controls who had been monitored over a lengthy period ranging from 
11 to 24 years (Table III.4), we aimed to reduce the likelihood of a false-negative 
selection. Similarly, identifying cases among patients who present with moderate to 
severe late effects soon after radiotherapy (ideally within 1 to 2 years post-radiotherapy) 
lessens the probability of a false positive selection, especially since such a patient 
population is likely to comprise mostly of intrinsically radiosensitive individuals 
(Figure IV.1). To further ensure that clinical phenotype of the patients truly reflects 
their intrinsic radiosensitivity, we attempted added measures of selecting cases and 
controls who had been exposed to favourable and unfavourable clinical factors known 
to influence normal tissue response after breast radiotherapy, respectively. However, as 
already explained, adhering to the stipulated criteria proved to be extremely difficult. 
Separately, considering the relatively small sample size of our cohort and the skewed 
nature of the patient selection process adopted in this study (where selected cases and 
controls were assumed to reflect extreme spectrums of intrinsic radiosensitivity), it 
would have been inappropriate analysing our data using the methods proposed by 
Dikomey et al. Ultimately, there are grounds to affirm the validity of the methods 
employed in our study, since after all, a comparative analysis of residual DSB levels in 
blood lymphocytes of cases and controls reveals higher levels of residual DNA damage 
among the clinically radiosensitive cohort.
IV.2.2 DSB repair as a biomarker of  clinical radiosensitivity
On the basis of experimental findings demonstrating an increased cellular 
radiosensitivity among syndromic and non-syndromic individuals presenting with an 
aggravated normal tissue response to radiotherapy, it was proposed that determination 
of cellular radiosensitivity using an in vitro cell-based assay could provide an estimate 
of an individual risk of normal tissue damage following radiotherapy [14–17]. To 
date, colony forming assay remains the gold standard approach to evaluating cellular 
radiation sensitivity, but performing this assay is time-consuming and laborious, 
notwithstanding the fact that culturing of primary cells requires an added level of 
expertise. Given the disadvantages, several surrogate cellular markers have been 
suggested and DSB repair is included among them.
It is widely agreed that DSB induced by ionising radiation if left unrepaired have an 
incredibly toxic effect on cells. In response to the induction of this lesion following 
radiation exposure, a range of molecular processes relating to checkpoint arrest and 
DSB repair is triggered within the cell nucleus to preserve the genomic integrity and 
physiological function of the cell. Nonetheless, in the event that DSB repair is impaired, 
a common assumption is that termination of cell viability through a variety of 
mechanisms such as apoptosis, autophagy, necrosis, or some form of mitotic 
Challenges of  predicting clinical radiosensitivity 93
catastrophe would ensue, thus preventing the erroneous replication of damaged 
genome. In this background, it would be intuitive to expect a close correlation between 
levels of residual DSB and loss of clonogenicity. This mechanistic relationship was also 
confirmed in experimental studies demonstrating a significant level of correlation 
between both cellular parameters in cell lines of radiotherapy patients and syndromic 
individuals, although in some of these reports, a positive association was only observed 
when certain experimental conditions were fulfilled [18–24].
Regardless of a correlation between cellular radiosensitivity and DSB repair, the 
verdict remains at large if assays of the latter cellular end-point predict for normal 
tissue responses in radiotherapy patients. Biological principles underlying the potential 
of the DSB repair assay for this purpose had been elaborated in the earlier chapters, 
and mostly they relate to the target cell model of normal tissue damage where tissue 
effects are a direct consequence of radiation-induced cell killing leading to a loss or 
inactivation of functional structural units within the irradiated tissue. Nonetheless, 
for several tissues, models not directly related to intrinsic radiosensitivity have been 
developed, showing the involvement of cytokine-mediated multi-cellular interactions 
in the radiation response [25, 26]. A fine example would be the release of extracellular 
TGFβ1, a cytokine with an established role in fibrogenesis, via oxidative and proteolytic 
cleavage from its latency-associated peptide following irradiation of mammary tissue 
[27]. In this model of radiation-induced fibrosis, no correlation with DSB repair or 
other related cellular end-points would be expected.
In breast radiotherapy patients who represented the 5% most damaged individuals 
within a cohort of women treated for early breast cancer using standardised 
radiotherapy protocols, we observed raised levels of residual DSB in blood lymphocytes 
24 hours after 4 Gy irradiation compared to that of controls. A similar observation was 
also noted in test irradiated skin tissues, albeit only in a subset of patients who likely 
represent the 0.1% and 1% most damaged population. Collectively, these study 
findings are in agreement with a mechanistic role of DSB repair in the pathogenesis of 
late normal tissue effects in radiotherapy patients. However, considering the complex 
inter-play of several molecular processes contributing to the onset of late radiation-
induced adverse effects, whether this cellular marker alone predicts for normal tissue 
radiosensitivity remains to be seen, and certainly the strength of this assay in predicting 
clinical radiosensitivity ought to be tested in a large scale prospective study.
IV.2.3 Potential clinical impact of  predictive testing of  normal tissue 
radiosensitivity
IV.2.3.1 Screening for ‘over-responders’ to radiotherapy
At first glance, it would appear that if a predictive assay of normal tissue radiosensitivity 
exists, such an assay would be of great value in clinical practice with various potential 
applications as had been discussed in Chapter I.2.1. The proposed applications are 
somewhat overlapping, and for the most part relate to the identification of individuals 
who are intrinsically radiosensitive, treating these patients with a lower radiotherapy 
dose or perhaps referring them to a different treatment option. In this scenario, the 
routine use of an assay to screen for ‘over-responders’ to radiotherapy would require 
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an extremely precise assay with a high positive predictive value. A positive predictive 
value refers to the probability that an individual is intrinsically radiosensitive if he or 
she receives a positive test result. Mathematically, it is defined by the formula shown 
below.
Positive predictive value = Number of  true positives/Number of  positive results1
From the above formula, it is evident that in order to achieve an assay with a strong 
positive predictive value, conditions of a high detection of true positive cases coupled 
with a low false detection rate (i.e. false positives) have to be fulfilled. However, as often 
encountered in the screening of lowly prevalent conditions, in this case clinical 
radiosensitivity, a common problem associated with an assay designed for this purpose 
is a low positive predictive value. To illustrate this argument, a reference is made to 
Figure IV.3 which is adopted from a 1997 editorial by Bentzen [28]. In this example, 
theoretical normal distributions of SF2, the parameter used to define individual cellular 
radiosensitivity, were plotted for cohorts of ‘over-responders’ (stippled) and the 
remaining normal population (full line), keeping in mind that the prevalence of the 
former patient group is probably about 1% of all radiotherapy patients [16, 17]. Means 
and coefficients of variation of SF2 were estimated to be 0.15 in ‘over-responders’, 0.37 
in normal individuals, and 20% in ‘over-responders’, 25% in normal individuals, 
respectively. A modest SF2 of 0.19 was then chosen as the threshold for classifying an 
individual as an ‘over-responder’, and true positive and false positive detection rates of 
‘over-responders’ are represented by areas under the stippled and full line plots to the 
1 Positive results include true and false positives.
Figure IV.3 Lognormal distributions of SF2 values in two hypothetical cohorts of ‘over-
responders’ (stippled) and normal individuals (full line). For the clarity of illustration, only 
the left hand tail of the latter distribution is shown in the graph. Reused with permission from 
Bentzen, 1997 [28].
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left of this threshold, respectively. Based on these estimates, a predictive assay of 
clinical radiosensitivity with this level of capability would yield a relatively high rate 
of true positive detection (≈ 90%), but only a fairly modest positive predictive value 
(≈ 65%) owing to the significant false positive detection rate. From this example, it is 
obvious that to derive an assay with a high positive predictive value of clinical 
radiosensitivity, the cellular parameter under test must be able to yield a wide separation 
between the two curves. Specifically, there should be a significant difference in cellular 
responses between ‘over-responders’ and the remaining normal population. The 
degree of inter-individual variation of this cellular end-point should ideally also be 
limited in both patient subsets.
Perhaps, a different approach can be undertaken with predictive assays of clinical 
radiosensitivity. Instead of applying the assays for the screening of ‘over-responders’, a 
more sensible and viable approach could entail using them as a negative predictive test 
to identify individuals who belong to the normal population. With reference once 
again to Figure IV.3, applying SF2 = 0.19 as the cut-off for defining an individual as a 
normal responder to radiotherapy, the negative predictive value of an assay can be 
easily determined by the areas under the stippled (false negative) and full line (true 
negative) plots to the right of this value. Quite evidently, contrary to the rather modest 
positive predictive value associated with an assay for predicting clinical radiosensitivity, 
it would seem that a strong negative predictive value is feasible for such a test. Given 
this possibility, it may be more practical implementing the assays for the screening of 
normal rather than clinically radiosensitive individuals.
IV.2.3.2 Modifying radiotherapy dose prescriptions according to individual intrinsic 
radiosensitivity
Another related rationale for a predictive assay of normal tissue radiosensitivity is to 
identify individuals within the sensitive tail of the distribution of normal tissue 
radiosensitivities. Empirically, this population of radiotherapy patients can be defined 
in relation to the dose at which incidence of late normal tissue complications among 
all patients would not exceed 5% at 5 years post-radiotherapy, a dose also commonly 
referred to as the TD5/5. Hence, individuals presenting with late adverse effects having 
received doses to normal tissues lower than the stipulated TD5/5 are classified as the 5% 
most clinically radiosensitive, and this would include the 1% most damaged ‘over-
responders’ mentioned in the earlier scenario. Again, the idea behind the identification 
of these clinically radiosensitive individuals rests on the notion that by referring these 
patients to other modalities of treatment, such as surgery and/or systemic therapy, a 
meaningful dose escalation may be possible in the remaining normal population. In 
theory, this should result in an improvement of tumour control while maintaining a 
comparable rate of late complications in the whole cohort.
To test this concept, we refer to a typical example of a dose-response curve for late 
normal tissue end-points, illustrated in Figure IV.4. As reported in the literature, dose-
response in late responding tissues is typically characterised by a steep dose gradient, 
implying that a small change in dose leads to a significant increment in response in 
these tissues [29–31]. In the graphs below, the stippled plots represent dose-response 
curves for an unselected population, while the super-imposed full line plots are 
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generated after excluding the 5% most clinically radiosensitive individuals. From these 
plots, it can be deduced that even with the exclusion of these intrinsically radiosensitive 
sub-population, total dose to normal tissue could only be increased by 3.1 Gy, 
corresponding to a mere 5.4% dose increment. The limited dose escalation is primarily 
due to the steep dose-response curve for late normal tissues. Based on this example, it 
is obvious that such a strategy is sub-optimal unless more patients are removed from 
the sensitive tail, which would allow for a more clinically meaningful dose escalation. 
Figure IV.4 Hypothetical example of a dose-response curve for late responding tissues 
generated based on a γ50 value of 4. Stippled and full line plots represent curves for an unselected 
population and a population cohort when 5% most clinically radiosensitive patients were 
excluded, respectively. Shaded areas indicate the 5% response level. Top and bottom (zoomed 
image of the shaded area) panels illustrate the possible dose increment from 57.1 to 60.2 Gy to 
normal tissues without exceeding the TD5/5 in a population where the 5% most radiosensitive 
subset is excluded from treatment. Reused with permission from Bentzen, 1997 [28].
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This would be in agreement with the conclusions by Burnet et al. where in their analysis, 
an 18% overall dose increment was possible but only in the 40% most resistant patients 
[32, Figure I.3].
IV.2.3.3 Improving therapeutic ratio: relationship between tumour control and late 
normal tissue complication probability models
Ultimately, the goal of a predictive assay of clinical radiosensitivity is to improve 
therapeutic ratio, either by lowering the rate of normal tissue complications through 
screening of clinically radiosensitive individuals or raising the tumour control 
probability by escalating doses in the remainder. It is therefore also important to 
scrutinised the possibility of achieving gains in tumour control probability as claimed 
in the latter context. For this exercise, an analysis of the dose-response curves for 
tumour control and late normal tissue complications was performed (Figure IV.5). 
Unlike the curves for late responding normal tissues, clinical dose-response curves for 
tumours are generally less steep. For example, in head and neck tumours, estimated γ37 
values ranged between 0.5 to 2.8, which is in stark contrast to values generated for late 
effects [33]. The difference in dose gradients between these curves impacts significantly 
on the potential therapeutic gains with dose escalation. Considering that a clinically 
detectable dose escalation would probably need to be in the order of 10% or more, it 
can be easily inferred from Figure IV.5 that the benefits of improving tumour control 
with a 10% increment in dose is only modest at best, whereas a disproportionate 
increment in late adverse events can be expected. This loss in therapeutic ratio is further 
amplified in tumours with a high tumour control probability where the steepness of 
the slope approaches zero. On this account, it discouraging to note that the expected 
gain with dose escalation, even if a reliable and robust predictive assay of clinical 
radiosensitivity were available, is marginal. Unfortunately, it would appear that the 
Figure IV.5 Hypothetical dose-response curves generated for tumour control (blue) and late 
normal tissue damage (red). Dotted line intercepting both curves is extrapolated from an 
arbitrary dose associated with 60% tumour control probability and 5% risk of late toxicities. 
Adapted from Barnett et al., 2009 with permission [31].
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maximum benefit from dose escalation is mainly derived at low levels of tumour 
control probability, but in such instances, one would even question the indication of 
radiotherapy in the first place.
IV.2.3.4 Potential strategies for the use of normal tissue radiosensitivity assays
Given the arguments put forth, it is clear that in order to exploit the clinical usefulness 
of normal tissue radiosensitivity assays, a knowledge on tumour radiosensitivity is 
required. Interestingly, findings arising from historical laboratory and clinical studies 
designed to examine a possible relationship between cellular radiosensitivities of 
tumours and normal tissues have suggested a significant host factor in modulating 
radiation responses of both tissues [34–37]. For example, tumours and normal tissues 
originating from mice harbouring the RS-SCID phenotype were significantly more 
radiosensitive compared to the wild-type counterparts [34]. Similarly in humans, A-T 
patients having received a sub-optimal dose due to the onset of severe clinical reactions 
to radiotherapy demonstrated remarkable tumour control with treatment which is 
usually considered inadequate [36]. In a study by West et al. from the Manchester 
group, tests of cellular radiosensitivity of tumour cells and lymphocytes from non-
syndromic cervical cancer patients were shown to be independently predictive of late 
normal tissue complications in these patients [37]. Collectively, these studies support 
the notion that intrinsic radiosensitivity of tumours and normal tissues are correlated, 
although it must be cautioned that findings inconsistent with the proposed notion have 
also been reported [38–40].
Assuming that an association between normal tissue and tumour radiosensitivity 
exists, a clinical situation where predictive testing of the former parameter may be 
useful relates to the modification of radiotherapy doses in clinically radiosensitive 
individuals. In this subset of patients, it is possible that dose-response of tumours 
differs from the average curves derived for the whole population. Although not a lot of 
information is available on this, it is probably within reason to postulate steep dose-
responses in both tumours and normal tissues of these patients. In this hypothetical 
situation, patients who are on the flat portion of the dose-tumour control probability 
curve are likely to benefit from a dose reduction if they are on the steep part of the 
dose-normal tissue complication curve, since this would only lead to a minor change 
in tumour control probability while impacting a marked change in their risks of late 
effects (Figure IV.6).
With the advent of modern radiotherapy techniques, such as intensity modulated 
radiotherapy (IMRT), image guided adaptive radiotherapy (IGRT), and stereotactic 
radiosurgery (SRS), radiation oncologists are progressively able to design treatment 
plans entailing prescription of high radiation doses to tumour targets while minimising 
irradiation of normal tissues. Conceptually, these new modalities aim to deliver a vast 
improvement in therapeutic ratio, and in the instance of head and neck cancers, the 
use of IMRT has been proven to reduce the incidence of late toxicities relating to 
dysfunction of salivary glands and swallowing [41, 42]. In this background, it is 
prudent to reconsider the potential advantages of predicting normal tissue responses 
to radiotherapy. Alluding to an earlier point made regarding the modest effects of dose 
escalation in a population of non-clinically radiosensitive individuals, a favourable 
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gain in therapeutic ratio would certainly be achievable if radiation doses in different 
orders of magnitude can be delivered to tumours and normal tissues.
IV.3 FUTURE PERSPECTIVES
The predictive assays of normal tissue radiosensitivity described in this thesis were 
mostly designed and tested in the early 90s. As alluded to in the earlier chapters, the 
results obtained with these traditional assays have been inconsistent, which may be 
unsurprising considering the complexity of pathological processes involved in the 
development of late clinical reactions to radiotherapy. In more recent times, interests 
have however shifted to establishing genetic profiles that may predict a patient’s 
probability of suffering toxicity following radiotherapy [43]. With the seminal 
discovery of the A-T phenotype, researchers have long postulated that genetic variation 
likely contributes to inter-individual differences in radiotherapy complications. This 
was later supported by small pilot studies reporting an association between variations 
in genes encoding proteins involved in the DDR and clinical radiosensitivity [44]. By 
the end of 1990s, it is largely agreed among researchers that individual radiosensitivity 
represents an inherited, polygenic trait. On this basis, a collective effort to screen for 
novel genetic variants associated with clinical radiosensitivity was initiated, and since 
the inception of a radiogenomics consortium in 2009, a flourish of studies investigating 
the relationship between genetic variants and normal tissue effects have been reported 
[45, 46]. Among the different possible variants, single nucleotide polymorphisms 
Figure IV.6 Modified illustration of Figure IV.5 with a super-imposed plot of a hypothetical 
dose-tumour control probability curve (stippled blue), generated on the assumption that dose 
gradients for tumour control and normal tissue damage are equally steep. In this example, a 
reduction in dose (indicated by the grey arrow) is associated with a minor effect on tumour 
control probability (shaded blue box), while late adverse effects are significantly reduced 
(shaded red box). Size of the shaded boxes reflects the magnitude of change. Adapted from 
Barnett et al., 2009 with permission [31].
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(SNPs) are most well characterised, although copy number variations (CNVs) also 
represent an important source of variation. Up until recently, SNPs association studies 
have been limited to the candidate gene approach, but with the advent of high 
throughput genotyping, it is now possible to approach the analyses of SNPs in a form 
of a single, large genome-wide association study (GWAS). Unlike the candidate gene 
approach where a gene will only be analysed if its function is well understood, GWAS 
avoids the need for prior knowledge, allowing for identification of novel disease loci 
within the human genome, even in non-protein coding regions. It is also important to 
note that large sample sizes are absolutely critical in studies investigating for an 
association between genotype and phenotype. Currently, a number of large scale 
studies based on a GWAS design are being conducted, and hopefully the approach 
undertaken by these studies will eventually yield a promising genotype which is 
predictive of normal tissue radiosensitivity [45, 47, 48].
On our end, DSB repair, chromosomal radiosensitivity, and radiation-induced 
apoptosis in ex vivo irradiated blood lymphocytes are currently being tested for an 
association with normal tissue responses of 400 breast and prostate cancer patients. 
Patients will be recruited among participants of two randomised trials, who are being 
prospectively monitored for late toxicities to radiotherapy [49, 50]. Although an 
association between radiation-induced apoptosis in lymphocytes and clinical 
radiosensitivity was not observed in our study, Azria and colleagues from the 
Montpellier group have been engaged as collaborators in this new project given their 
successes with the assay [51]. Through this large scale prospective study, we hope to 
conclusively address the value of these singular cellular end-point assays for predicting 
normal tissue radiosensitivity.
IV.4 FINAL CONCLUSIONS
Predictive assays of normal tissue radiosensitivity have often been referred to as the 
‘holy grail of radiotherapy’, which bears the connotation of something intensely 
sought but never found [52]. While the current in vitro assays have at times demonstrated 
a statistically significant correlation between a cellular end-point and clinical 
radiosensitivity, the real obstacle is to develop an assay which is reproducible and 
possesses the power to precisely predict individual normal tissue outcomes following 
radiotherapy. With the introduction of newer and more robust approaches involving 
multi-centre collaborations in GWAS and large scale well designed prospective studies, 
one can only hope that we are now better equipped in the pursuit of the ‘holy grail’. 
Otherwise, it may well be that after years of research into predicting normal tissue 
radiosensitivity, the only real gain, at the end of it all, is merely an improved 
understanding of normal tissue radiobiology.
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Glossary
ANOVA Analysis of variance
A-T Ataxia-telangiectasia
ATLD A-T line Disorder
ATM Ataxia-telangiectasia mutated
BRCA1/2 Breast cancer 1/2
Cdc25 Cell division cycle 25
Cdk Cyclin-dependent kinase
Chk2 Checkpoint kinase 2
CNV Copy number variation
CtIP C-terminal binding protein interacting protein
CTCAE Common terminology criteria for adverse events
CTGF Connective tissue growth factor
D0.1 Dose required to reduce survival fraction to 0.1
DDR DNA damage response
DNA-PK DNA-dependent protein kinase
DSB DNA double-strand break
Exo1 Exonuclease 1
γ37 Normalised slope of the dose-response curve at 37% response level
γ50 Normalised slope of the dose-response curve at 50% response level
GWAS Genome-wide association study
H2AX Histone 2A variant
γH2AX Phosphorylated histone 2A variant
HR Homologous recombination
HSP4 Heat shock protein 47
IL-13 Interleukin-13
IGRT Image guided adaptive radiotherapy
IMRT Intensity modulated radiotherapy
KAP1 KRAB-associated protein 1
LIG4 Ligase 4
MDC1 Mediator of DNA damage checkpoint protein 1
MRE11 Meiotic recombination element 11
MRN MRE11/Rad50/NBS1
NBS1 Nijmegen breakage syndrome 1
NHEJ Non-homologous end-joining
PI3KK Phosphatidylinositol 3-kinase-related kinases
RPA Replication protein A
RS-SCID Radiosensitive-Severe combined immunodeficiency
RT Radiotherapy
SNP Single nucleotide polymorphism
SRS Stereotactic radiosurgery
106 Glossary
SF Surviving fraction
SF2 Surviving fraction at 2 Gy
ssDNA Single strand DNA
TD5/5  Threshold dose at which incidence of normal tissue complications 
does not exceed 5% at 5 years post-radiotherapy
53BP1 Tumour suppressor p53 binding protein 1
TGFβ1 Transforming growth factor β1
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labelling
XRCC2/3/4 X-ray cross complementation group 2/3/4
XLF XRCC4-like factor
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